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INTRODUCTION 
 
“The biggest obstacles in our lives are the barriers our mind creates…” 
(unknown author)
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1. Blood-Brain Barrier 
The central nervous system (CNS) microenvironment requires an appropriate 
homeostasis for the neuronal function, which is preserved by the blood–brain barrier (BBB). The 
primary role of the BBB is the regulation of brain microenvironment by restricting ionic, fluid and 
cell movements between the blood and brain, as represented in Fig.1, while contributing to 
supply essential nutrients and remove secretion and excretion products (Deli 2007). 
 
 
 
 
 
 
 
 
The BBB is part of the neurovascular unit and can be modulated by the crosstalk  
between brain endothelial cells (ECs), perivascular microglia, astrocytes, pericytes and neurons 
(Bradbury 1993), represented in Fig.2 The barrier-conferring properties of the BBB are the ECs 
of the brain capillaries. However, associated pericytes, astrocytes and the surrounding the 
basement membrane also play an additional structural and regulatory role (Balda, Whitney et al. 
1996; Chen, Hori et al. 2011; Toborek M., Seelbach et al. 2013).  
The BBB is composed of specialized non-fenestrated brain microvascular endothelial 
cells (BMVECs) tightly connected in an impermeable monolayer devoid of transcellular pores 
(Yamamoto, Ramirez et al. 2008; Reynolds, Mahajan et al. 2011; Toborek M., Seelbach et al. 
2013). Epithelial cells contain also other specialized membrane domains at the lateral 
Fig.1 Molecules flux across the blood–brain barrier (BBB). Schematic diagram of the endothelial cells 
showing the main routes for molecular traffic across the BBB. The tight junctions (a) restrict penetration of 
water-soluble compounds, including polar drugs. In b is represented the effective diffusive route for lipid-
soluble agents and in c, transport proteins (carriers) for glucose, amino acids, purine bases, nucleosides, 
choline and other substances are represented. Specific receptor mediated-endocytosis and transcytosis are 
responsible for the transport of specific molecules (d). In e native plasma proteins are poorly transported, 
although cationization can increase their uptake by adsorptive-mediated endocytosis and transcytosis. Most 
CNS drugs enter via route b. Adapted from Abbott NJ, 2006. 
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membranes for intercellular adhesion - adherens junctions (AJs), desmosomes and Gap 
Junctions. In these domains, cadherin, and desmoglein/desmocollin were identified as major 
integral membrane proteins (Brown, Morris et al. 2007). The presence of tight junctions (TJs) at 
the apical part is responsible for the regulation and proper maintenance of BBB integrity 
(András, Hong et al. 2003; Yamamoto, Ramirez et al. 2008; Reynolds, Mahajan et al. 2011; 
Toborek M., Seelbach et al. 2013), as well as for the restriction of paracellular flux and the 
maintenance of polarity of enzymes and receptors on luminal and abluminal membrane 
domains (Deli 2007), shown in Fig.3.  
 
 
 
 
 
Brain endothelial cells are distinct from the other endothelial cells because they are 
endowed with particular characteristics: very low levels of transcellular endocytosis; expression 
of specific transporters in a polarized manner; and formation of a low permeability physical 
barrier between the blood and the brain due to the presence of TJs between adjacent 
endothelial cells (Brown, Morris et al. 2007; Reynolds, Mahajan et al. 2011). TJs are specialized 
membrane domains that seal the intercellular spaces in epithelia and endothelia and thus 
contributing to the permeability barrier between luminal and interstitial compartments. TJs 
confer also selectivity to the transepithelial flux of molecules and ions through the intercellular 
spaces between epithelial cells (Balda, Whitney et al. 1996; Zoia, L et al. 2000). TJs are 
composed of claudins and occludin, intracellular accessory proteins (Zonnula occludens - ZO-1 
to ZO-3), as well as junctional associated molecules (JAM) (Zoia, L et al. 2000; Yamamoto, 
Ramirez et al. 2008; Chen, Hori et al. 2011; Toborek M., Seelbach et al. 2013).  
Occludin (65-kDa protein) was the first TJ identified and it is highly expressed in 
BMVECs, consistently found along the cell borders of brain endothelium (Yamamoto, Ramirez 
et al. 2008; Kashiwamura, Sano et al. 2011). Occludin is composed of four transmembrane 
domains with the carboxyl and amino terminals oriented to the cytoplasm and two extracellular 
Fig.2 Neurovascular unit components. The barrier is formed by 
microvascular endothelial cells, surrounded by basal lamina and astrocytic 
endfeet, which are essential to provide the cellular link to the neurons. The 
figure also shows pericytes and microglial cells surrounding neurovascular 
unit. Source: Adapted from Abbott NJ, 2013. 
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loops spanning the intercellular space. The extracellular loops interact with similar loops of 
occludin in the neighboring cells to form TJs. The role played by the N-terminal domain of 
occludin is not known but the C-terminal domain interacts with intracytoplasmic proteins, 
including ZO-1, ZO-2, and ZO-3 (Yamamoto, Ramirez et al. 2008; Rao 2009; Chen, Hori et al. 
2011). The amount of occludin in endothelial cells of the nervous system is higher that on the 
other endothelial cells, suggesting a particularly active role in BBB function (András, Hong et al. 
2003; Yamamoto, Ramirez et al. 2008).  
 
 
 
 
 
 
Claudins (24-kDa) are also major structural and functional elements of TJs in 
endothelial cells, and they have been shown to be a critical determinant of BBB permeability 
(András, Hong et al. 2003; Yamamoto, Ramirez et al. 2008). Up to 24 claudins have been 
identified in mammals, sharing a high sequence homology in the first and fourth transmembrane 
domains. Endothelial cell borders are enriched in claudins, both in and outside the CNS. 
Claudins express high tissue and cell-type specificity and claudins-3 and 5 are the most 
abundant in the brain endothelium. The interaction of the extracellular loops of claudins ensures 
the tightness of the contact between the cells of the monolayer (Yamamoto, Ramirez et al. 
2008). Claudins are involved in both paracellular sealing and membrane domain differentiation. 
Within the large family of claudins, claudin-1 and claudin-5 seem to be the most important 
concerning structure and function of the TJs on BBB. Claudin-5 localizes primarily on the 
external leaflet of endothelial cell membranes, whereas claudin-1 is associated with the internal 
membrane leaflet. The tightness of the BBB may depend on the ratio of claudin-1 to claudin-5. 
Claudin-5 is recognized as endothelial-specific and it is the most important TJ involved in 
maintaining the BBB function. In mouse brain capillary endothelial cells, claudin-5 was reported 
Fig.3 Protein complexes regulation Blood-Brain Barrier permeability. Tight Junctions are represented in the most 
apical part of the lateral membrane of adjacent cells. Adhering junctions, desmosomes and Gap Junctions are also 
represented, progressively located in a more basal part of the endothelial cell membrane.  
Source:http://keepinapbiologyreal.wikispaces.com/Extracellular+Components 
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to be the most abundantly expressed at the mRNA level (Liebner, Kniesel et al. 2000; 
Kashiwamura, Sano et al. 2011). This fact justifies that claudin-5 is also the most studied 
(Haorah, Knipe et al. 2005; Brown, Morris et al. 2007; Forster, Burek et al. 2008; Mahajan, 
Aalinkeel et al. 2008; Yamamoto, Ramirez et al. 2008; Abdul Muneer, Alikunju et al. 2011; 
Kashiwamura, Sano et al. 2011; Martins, Baptista et al. 2011; Schrade, Sade et al. 2012).  
The role of each TJ on BBB formation and maintenance is a relevant research topic.  
Although overexpression of claudins can induce cell aggregation and formation of TJ-like 
structures, the expression of occludin does not result in TJ formation (Yamamoto, Ramirez et al. 
2008). In fact, functional TJs can be formed in the absence of the occludin gene and protein 
expression (András, Hong et al. 2003). It seems that claudins form the primary makeup of the 
TJs, and occludin further enhances TJ tightness and plays regulatory processes (Furuse, 
Hirase et al. 1993; András, Hong et al. 2003; Yamamoto, Ramirez et al. 2008; Rao 2009). 
Cytoplasmic accessory proteins ZO-1, ZO-2 and ZO-3 belong to the family of 
membrane-associated guanylate kinase homologues (MAGUK) that link TJs to the 
cytoskeleton. Although the correlation between ZO-1 and the TJs is strong, former reports 
indicate that ZO-1 expression is not correlated with paracellular barrier function (Hawkins and 
Davis 2005). Among ZO accessory proteins, ZO-1 was first identified as a peripheral membrane 
protein with a molecular mass of 220-kDa and highly concentrated at TJs in 
epithelial/endothelial cells, as well as on cardiac muscle cells, fibroblasts and astrocytes. In the 
brain, ZO-1 and ZO-2 function as cross-linkers between occludin and the cytoskeleton. While 
ZO amino-terminal domain bounds directly to the cytoplasmic C-terminal of occludin, the 
carboxyl-terminal was shown to provide connection to the actin cytoskeleton filaments, both in 
vitro and in vivo (Masahiko, Kazumasa et al. 1999; Mahajan, Aalinkeel et al. 2008; Toborek M., 
Seelbach et al. 2013), that allows the TJ to form a tight seal while still remaining capable of 
rapid modulation and regulation (Reynolds, Mahajan et al. 2011). Moreover, some findings 
reveal that ZO-1 is recruited to normal TJs through direct or indirect interactions not only with 
occludin but also with claudin (Masahiko, Kazumasa et al. 1999). Interestingly, the stabilization 
of TJs provided by intracellular proteins such as ZO, and transmembrane proteins such as β-
dystroglycan, allow the crosslink between the astrocytic endfeet and endothelial cells at the 
basal lamina (Northrop and Yamamoto 2012). For their peculiar localization, ZO-1 and ZO-2 
accessory proteins serve as recognition proteins for TJ placement and act as support structures 
for signaling proteins (Reynolds, Mahajan et al. 2011; Toborek M., Seelbach et al. 2013). Up on 
that, F-actin filaments are involved in the maintenance of cytoplasmic domains and adhesion, 
essentially when linked to the accessory proteins of TJs (Matthias, M et al. 2004; Navarro-
Costa, Plancha et al. 2012). As such, signaling molecules that directly control actin cytoskeleton 
organization are of particular significance with regard to TJ function regulation (Matthias, M et 
al. 2004; Mahajan, Aalinkeel et al. 2008). All together these data allow verifying that 
cytoskeleton and TJs are strictly related. 
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1.1 BBB models 
In the last three decades, a great number of BBB models based on cell cultures have 
been developed. Primary cultures of cerebral ECs were firstly used as monolayers for 
experiments, and later, immortalized cell lines have been established and extensively used for 
that purpose (Deli 2007). In fact, the difficulty in maintaining primary ECs in culture is a 
challenge often overtaken by immortalized cell lines utilization, which are easier to culture and 
maintain and represent a useful material for in vitro BBB experiments (Omidi, Campbell et al. 
2003; Roux and Couraud 2005; Brown, Morris et al. 2007; Yamamoto, Ramirez et al. 2008; 
Booth and Kim 2012; Takeshita, Obermeier et al. 2014). Several experiments were carried out 
using an in vitro BBB model to better mimics BBB response to several pathophysiological 
stimulus (Brown, Morris et al. 2007; Ramirez, Potula et al. 2009; Chen, Hori et al. 2011; Urrutia, 
Rubio-Araiz et al. 2013). The most common co-culture for BBB integrity assessment is 
composed by ECs and astrocytes (Mahajan, Aalinkeel et al. 2008; Booth and Kim 2012; 
Takeshita, Obermeier et al. 2014) although different cell components of BBB may be used for 
other purposes. Often, assessing relevant signaling cascades from the neurovascular unit that 
affect BBB properties requires co-culture systems containing glial cells, neurons, or pericytes. 
These models are valuable tools to study cell–cell interaction in the neurovascular unit, and 
modulation of BBB permeability in both physiological, pathological, and pharmacological 
conditions (Deli 2007). 
As stated above, ECs and astrocytes co-cultures are the most common combination, 
allowing to assess the influence of astrocytes modulation over ECs permeability and barrier 
integrity (Booth and Kim 2012; Takeshita, Obermeier et al. 2014). Astrocytes and microglial 
cells or astrocyte‐produced factors enhance endothelial TJ in vitro. These data are further 
supported by the finding that removal of astroglia from a co-culture of brain ECs led to an 
increase in permeability for sucrose and peroxidase which occurs without effective loosening of 
TJs (Abbott, Rönnbäck et al. 2006; Deli 2007). 
The tight paracellular barrier is a fundamental characteristic of BBB and the 
measurement of the transendothelial electrical resistance (TEER) is one of the most 
straightforward methods to evaluate it. In culture conditions, TEER reflects the junctional 
permeability for sodium ions. All relevant models must show a sufficient tightness (150–200 
Ω.cm
2
) to allow the study the permeability or transport of molecules. Considering animal cell 
lines, the best characterized mouse lines are TM‐BBB4 and b.End3 showing higher basal 
values of TEER (Deli 2007). 
Because BBB damage is recognized as an early event in many neurological conditions, 
understanding BBB signaling has become a relevant research topic, and also a therapeutic 
target (Abbott 2013). In our work, we are interested in better understand the mechanisms that 
lead to BBB disruption under exposure to psychostimulant drugs, such as amphetamines 
(Martins, Baptista et al. 2011; Park, Kim et al. 2013), and in particular how ALC may contribute 
to preserve BBB integrity (Haorah, Floreani et al. 2011; Muneer, Alikunju et al. 2011). 
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2. Methamphetamine 
Methamphetamine (METH) is a potent stimulant with strong euphoric and reinforcing 
properties producing short and long-lasting neurotoxic effects. METH is synthetically produced 
and easily abused (Melega, Cho et al. 2007; ElAli, Urrutia et al. 2012), being the second most 
commonly used type of illicit substances worldwide, and the most used Amphetamine-type 
stimulant (Fig.4), with 15–16 million estimated users (Crime 2014). A common pattern in METH 
abuse starts with daily exposure to increasing doses followed eventually by engagement in 
multiple daily administrations. METH blood levels allow to estimate an intake of about 260 mg in 
a pattern of 3 to 4 binges per day (Melega, Cho et al. 2007; Ramirez, Potula et al. 2009; Urrutia, 
Rubio-Araiz et al. 2013), reaching high plasma levels, in an half-life of 12-16h (Melega, Cho et 
al. 2007; Krasnova and Cadet 2009).  
 
 
 
 
 
After METH intake, consumers experience a sense of euphoria, hypersexuality, 
increased productivity and energy, with decreased anxiety. However, both short- and long-term 
abuse of METH leads to deleterious and long-lasting neurotoxic effects. METH-abuse negative 
consequences include acute toxicity, altered behavioral and cognitive functions and long-term 
neurological damage. Consumption of large doses induce more severe consequences including 
hyperthermia above 41°C, renal and liver failure, cardiac arrhythmias, heart attacks, 
cerebrovascular hemorrhages, strokes and seizures (Albertson, Derlet et al. 1999). Chronic 
abuse of METH contributes to attention deficits, anxiety, depression, aggressiveness, social 
isolation, psychosis, mood disturbances, and psychomotor dysfunction. Neuropsychological 
deficits in motor skills, and in executive and episodic memory observed after METH intake are a 
consequence of METH effect at the dopamine rich fronto-striato-cortical loops. In addition, 
METH abusers show impaired decision-making and impulsivity, which was associated with the 
Fig.4. Source: UNODC annual report questionnaire and other official sources.  
Note: Total ATS includes amphetamine, “ecstasy”-type substances, methamphetamine, non-specified ATS, other 
stimulants and prescription stimulants 
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executive aspects of working memory deficits (Gold, Kobeissy et al. 2009; Krasnova and Cadet 
2009). METH withdrawal is also associated with anhedonia, irritability, fatigue, impaired social 
behavior and intense craving for the drug (Krasnova and Cadet 2009). 
METH-toxicity has been characterized by the disruption of monoamine production and 
synaptic integrity (Bowyer, Thomas et al. 2008; Ramirez, Potula et al. 2009; Urrutia, Rubio-Araiz 
et al. 2013), schematically represented in Fig.5. METH-neurotoxicity is characterized by long-
term reduction in dopaminergic and serotonergic functions, including depletion of dopamine 
transporter (DAT), serotonin transporter (SERT), serotonin (5-HT) and dopamine (DA). The 
postmortem analysis of the brain of a METH consumer revealed that DA, tyrosine hydroxylase 
(TH), and the DAT are reduced. Nowadays, magnetic resonance imaging techniques performed 
in METH chronic users confirm those brain changes (Imam, El-Yazal et al. 2001; Chandramani 
Shivalingappa, Jin et al. 2012). In rodents and non-human primates METH was seen to induce 
long-term depletion of DA metabolism, decreasing the number of high affinity DA uptake sites 
and reducing the activity of TH in striatum (caudate and putamen). Moreover, the findings of 
long-term reduction of dopaminergic markers in animal brains, together with histological signs 
suggestive of nerve terminal injury following acute exposure, led to the conclusion that METH 
damages brain dopamine nerve endings (Mirecki, Fitzmaurice et al. 2004; Gold, Kobeissy et al. 
2009).  
 
 
 
 
Fig.5 Schematic representation of cellular and molecular events involved in METH-induced neurotoxicity. 
mA- methamphetamine; GLU- glutamate; DA- Dopamine; DAT- Dopamine transporter; ROS- Reactive Oxygen Species.  
Source: (Marshall and O'Dell 2012) 
 
  
10 
 
Although the mechanism underlying METH-induced brain damage in dopamine neurons 
is not fully understood, oxidative stress is seen as an early event in this mechanism, which 
could possibly be related with the excessive release or intraneuronal mobilization of dopamine 
and formation of toxic dopamine-derived oxyradical (Mirecki, Fitzmaurice et al. 2004). Several 
studies in the literature show a well supported role for oxygen (ROS) and nitrogen-based (RNS) 
radicals, where ample evidence depicts the importance of peroxynitrite in METH-induced 
dopaminergic neurotoxicity (Imam, El-Yazal et al. 2001; Jin, Moo et al. 2002; Chandramani 
Shivalingappa, Jin et al. 2012). METH enters the dopaminergic neuron through DAT and 
displaces vesicular dopamine (Chandramani Shivalingappa, Jin et al. 2012). The increased 
content of amines in the cytoplasm leads to high levels of oxidation forming highly reactive 
dopamine quinones and reactive oxygen species, leading to increased oxidative stress. Besides 
the toxic effects of METH on monoaminergic terminals, there is evidence of the activation of 
genes related to cell death which can cause death to the cell by both apoptotic and necrotic 
mechanisms. METH-induced cell death was observed in the hippocampus, parietal cortex, 
striatum and in several other brain regions (Gold, Kobeissy et al. 2009). Moreover, METH 
induces autophagy in neurons which is associated with the formation of ubiquitin-positive, α-
synuclein aggregates and multilamellar bodies after METH administration in DA containing 
neurons (Pasquali, Lazzeri et al. 2008; Ma, Wan et al. 2014).  
Chronic exposure to METH can also lead to changes in brain metabolism and energy 
requirements, which are region specific (Downey and Loftis 2014). Mitochondrial dysfunction 
has been implicated in the neurodegeneration mechanisms caused by METH. In fact, exposure 
to METH decreased mitochondrial membrane potential, increased mitochondrial mass and 
protein nitrosylation, and decreased levels of different subunits from complexes I, III, and IV of 
the electron transport chain (Chandramani Shivalingappa, Jin et al. 2012). METH exposure 
significantly inhibits glucose uptake by neurons and astrocytes (Muneer, Alikunju et al. 2011) 
and the drug neurotoxicity generates a strong and lasting glial response, resulting in astrogliosis 
and release of inflammatory mediators (Goncalves, Baptista et al. 2010). Moreover, microglial 
activation has also been reported in the brain of METH abusers using Positron Emission 
Tomography (PET) imaging techniques (Gold, Kobeissy et al. 2009).  
Recently, the brain endothelium has also been shown to be a target of METH toxicity, 
since it represents a component of major importance in the BBB. However, the effect of METH 
on the brain endothelium remains largely under-characterized. 
 
 
2.1  Methamphetamine effects on BBB function 
BBB impairment contributes to many pathological states such as inflammation, tumor 
differentiation (Singh and Harris 2004), epilepsy, Parkinson’s and Alzheimer’s diseases, multiple 
sclerosis and ischemia/reperfusion (Forster, Burek et al. 2008). 
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In the last decades, the effects of METH exposure in BBB have been extensively 
recorded (Bowyer, Thomas et al. 2008; Mahajan, Aalinkeel et al. 2008; Abdul Muneer, Alikunju 
et al. 2011; Northrop and Yamamoto 2012; Martins, Burgoyne et al. 2013; Urrutia, Rubio-Araiz 
et al. 2013). METH exposure impairs glucose transport and uptake in ECs (Abdul Muneer, 
Alikunju et al. 2011), increases eNOS activation and transcytosis (Martins, Burgoyne et al. 
2013; Ma, Wan et al. 2014), decreases BBB tightness along with a decrease in the expression 
of cell membrane-associated TJs proteins (Ramirez, Potula et al. 2009). 
The physiopathological processes involved in some neurological diseases and in 
METH-induced dysfunction seem to be similar. Fortunately, METH exposure studies in in vitro 
models raise the possibility to explore the mechanisms of action involved. Likewise, possible 
therapeutic or protective tools can also be explored using these models.  
 
2.1.1 Increased permeability of the BBB 
METH-induced increased BBB permeability was consistently reported both in vivo and 
in vitro (Bowyer, Thomas et al. 2008; Abdul Muneer, Alikunju et al. 2011; ElAli, Urrutia et al. 
2012; Urrutia, Rubio-Araiz et al. 2013). In vitro, different models of cell lines and primary ECs 
were used for the assessment of METH effects and all of them showed a reduced TEER after 
the drug exposure (Mahajan, Aalinkeel et al. 2008; Ramirez, Potula et al. 2009; Martins, 
Burgoyne et al. 2013). Evaluation of BBB integrity by the quantification of the transendothelial 
migration of peripheral blood mononuclear cells (PBMC) across the BBB has also shown a 
significantly increase in the percentage of PBMC transmigration after METH exposure 
(Reynolds, Mahajan et al. 2011). In vivo, the most frequent approach consists in the 
measurement of macromolecular tracers that cross the BBB. Using those protein-tracers as well 
as IgG extravasation, METH was shown to induce marked disruption of BBB causing massive 
leakage of such molecules across the barrier in the cerebral cortex, hippocampus, thalamus, 
hypothalamus, cerebellum and amygdale of METH-treated mice (Bowyer, Thomas et al. 2008; 
Krasnova and Cadet 2009; Conant, Lonskaya et al. 2011; Martins, Baptista et al. 2011). 
The decrease in the tightness of ECs monolayers induced by METH occurs in a dose- 
and time-dependent manner (Ramirez, Potula et al. 2009) and may be caused by decreased 
expression of cell membrane-associated TJs, concomitant with enhanced ROS production 
(Ramirez, Potula et al. 2009; Mahajan, Aalinkeel et al. 2012; Park, Kim et al. 2013) and 
activation of cytoskeleton-related protein expression (Ramirez, Potula et al. 2009; Park, Kim et 
al. 2013).  
 
2.1.2 Reduction and/or redistribution of TJs  
Dynamic regulation of TJs function is fundamental to many physiological processes. TJs 
disruption drastically alters paracellular permeability which is the hallmark of many pathological 
states - ischemia/reperfusion, inflammation, tumor differentiation (Singh and Harris 2004). The 
increased permeability of BBB after METH exposure is accompanied by the reduction and/or 
redistribution of adhesion molecules – essentially claudin-5 and occludin (Reynolds, Mahajan et 
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al. 2011; Northrop and Yamamoto 2012; Toborek M., Seelbach et al. 2013). Reduction of TJs is 
strictly related with BBB increased permeability. Such events were reported in cultured brain 
microvascular endothelial cells (Ramirez, Potula et al. 2009; Abdul Muneer, Alikunju et al. 2011; 
Reynolds, Mahajan et al. 2011) and in mouse brain (Bowyer and Ali 2006; Martins, Baptista et 
al. 2011). METH was shown to reduce the expression of claudin-3, JAMs, ZO-1 and ZO-2 both 
at the protein and mRNA levels (Mahajan, Aalinkeel et al. 2008). Simultaneously, METH 
induces the expression of the pro-inflammatory cell adhesion molecules ICAM-1 and VCAM-1 in 
cerebral microvessels (Toborek M., Seelbach et al. 2013). However, in light of several reports it 
seems that decrease TJs occurs by the effect of METH on protein turnover rather than on gene 
expression (Ramirez, Potula et al. 2009). Importantly, immunoreactivity of those proteins after 
METH exposure is also characterized as fragmented (Toborek M., Seelbach et al. 2013), with 
formation of gaps (Ramirez, Potula et al. 2009), which contrast with the continuous labeling  
observed in control conditions. Changes in claudins and occludin are a common outcome of 
METH exposure. However, several studies show that ZO-1 or ZO-2 seem to be unaffected 
(Ramirez, Potula et al. 2009; ElAli, Urrutia et al. 2012). 
Besides disruption and decrease in protein levels, an important finding observed after 
METH exposure is the translocation/redistribution of TJs. The most frequent pattern described 
in the literature is the translocation of claudin-5 from the membrane to the cytosol (Ramirez, 
Potula et al. 2009). Recent studies observed that also occludin shares this pattern after METH 
exposure through endocytosis in vesicles (Toborek M., Seelbach et al. 2013). 
However, there are reports where repeated low doses of METH administered to mice 
led to increased permeability of cerebral microvessels without disrupting structural proteins 
(ElAli, Urrutia et al. 2012). Other study showed that primary ECs exposed to low doses of METH 
display increased TEER without changes in adherens junctions and TJs (Martins, Burgoyne et 
al. 2013). 
 
2.1.3 Release of pro-inflammatory cytokines and chemokines 
There is evidence of BBB disruption in central nervous system (CNS) pathologies 
characterized by a relevant neuroinflammatory component. In fact, increase of pro-inflammatory 
cytokines such as tumor necrosis factor (TNF) and interleukins are associated with changes in 
BBB integrity in several neurological diseases. In vitro studies have shown that TNF, interferon-
gamma (IFN-γ) and interleukin-1beta (IL-1β) are involved in the disruption of BBB integrity 
(O'Shea, Urrutia et al. 2014). 
The role of neuroinflammation in the BBB structure and function following METH 
exposure were investigated. Recent data showed that METH-induced neurotoxicity may result 
from a synergistic response of different cellular entities in which glial cells play an important role. 
Indeed, METH exposure results in astrogliosis (activation of both astrocytes and microglial cells) 
along with pro-inflammatory cytokines release (Ladenheim, Krasnova et al. 2000; Ramirez, 
Potula et al. 2009; Goncalves, Baptista et al. 2010; Northrop and Yamamoto 2012). Microglial 
activation appears to be an early event in the neurotoxic cascade initiated by METH exposure, 
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with cytokines release driving at least part of its neurotoxic effects. Importantly, METH seems to 
induce a substantial microglial response in the areas of the brain that show increased neuronal 
degeneration after exposure (Friend and Keefe 2013). Some anti-inflammatory drugs afford 
protection against METH-induced microgliosis and neurotoxicity, but additional investigation 
needs to be carried out (O'Shea, Urrutia et al. 2014). 
Neuroinflammation mediates METH toxicity to monoamine terminals but its role in 
METH-induced BBB disruption is far from being understood. It was reported that an acute high 
dose of METH induces an increase in the expression levels of IL-6 mRNA and TNF-α mRNA in 
some brain regions, soon after exposure (Goncalves, Baptista et al. 2010). Moreover, METH 
neurotoxicity is attenuated in the IL-6 knockout mice, where a decrease in reactive gliosis 
marker was observed (Ladenheim, Krasnova et al. 2000). METH also increases the pro-
inflammatory cytokine interleukin-1β levels (Krasnova and Cadet 2009). The inflammatory 
mediator cyclooxygenase (COX) has been implicated in BBB disruption and it was shown 
increased after METH exposure. Increases in glial fibrillary acidic protein (GFAP) and COX-2 
expression in endothelial brain capillaries occurred with BBB disruption a few days after METH 
exposure in combination with stress (Northrop and Yamamoto 2012). Moreover, nonselective 
inhibition of COX attenuated TNF-induced BBB disruption. Of note, is still unclear whether 
reactivity of astrocytes surrounding the capillaries is a cause or a consequence of BBB damage 
induced by METH. Collectively, these data indicate that ECs respond to the METH-insult by 
producing inflammatory mediators that can cause damage to the BBB (Northrop and Yamamoto 
2012). 
Microglia might potentiate METH-related damage by releasing neurotoxic substances 
such as superoxide radicals and NO (Krasnova and Cadet 2009) and some authors suggested 
that both oxidative mechanisms and cytokines might exert their effects through modulation of 
transcriptional factors. However, BBB damage could also result from TJs disruption. There is 
evidence that TJs and ZO are highly sensitive to the microenvironment and in vitro respond to 
inflammatory cytokines by displaying altered subcellular localization and dissociation of the 
occludin/ZO complex (Mahajan, Aalinkeel et al. 2008). 
 
2.1.4 Increased activity and expression of MMP-2/9 
Matrix metalloproteinases (MMPs) play significant roles in complex processes, including 
regulating cell behavior, cell-cell communication and tumor progression. MMPs mediate several 
proteolytic reactions involving cellular surface elements such as adhesion molecules, receptors 
and intercellular junction proteins. MMPs belong to a family of proteolytic enzymes of more than 
20 members that require the binding of Zn
2+
 for their enzymatic activity (Visse and Nagase 
2003; Conant, T Lim et al. 2012; Mizoguchi and Yamada 2013). MMP-9 is up-regulated 
following various types of insults to the brain, and it has been seen as a marker of 
neurodegeneration (Liu, Brown et al. 2008). MMP-9 has been observed to play relevant roles 
both in vitro and in vivo in different pathological conditions such as brain ischemia and trauma, 
while the closely related relative MMP-2, does not play a role in those events (Ramirez, Potula 
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et al. 2009). In vivo increased MMP-9 activity was reported in specific brain regions, namely 
those involved in drug addiction (Mizoguchi, Yamada et al. 2007; Liu, Brown et al. 2008; 
Martins, Baptista et al. 2011; Urrutia, Rubio-Araiz et al. 2013) but the cellular source of this 
protease is not exactly known. Neurons and/or microglia as a source have been suggested but 
a peripheral origin from leukocytes could also be possible. It was demonstrated that ECs 
secrete MMP-9 in the basal direction, which facilitates the degradation of the basal membrane. 
Basal membrane degradation has been associated with an increase in vascular permeability 
and the loss of vascular integrity leading to edema and leukocyte infiltration (Urrutia, Rubio-
Araiz et al. 2013).  
Chen F et al, 2011 demonstrated that MMP-9 induces significant changes to occludin in 
ECS both in vitro and in mice brains. Moreover, the use of specific monoclonal antibodies 
against MMP-9 attenuate brain extravasation and edema in some pathological conditions. 
Experiments with endothelial model bEnd.3 cells allow to conclude that MMP-9 increases BBB 
permeability, which was attenuated when cells are co-transfected with endogenous MMPs 
inhibitors (Chen, Hori et al. 2011).  
Activation and expression of MMPs is a common mechanism of BBB leakiness, and has 
been reported after METH exposure (Liu, Brown et al. 2008; Conant, Lonskaya et al. 2011; 
Martins, Baptista et al. 2011; Reynolds, Mahajan et al. 2011; Conant, T Lim et al. 2012; Urrutia, 
Rubio-Araiz et al. 2013). Different in vivo experiments demonstrate that METH produces an 
increase in both striatal MMP-9 expression and gelatinolytic activity occurring along with an 
increase in the degradation of extracellular matrix components and BBB permeability (Liu, 
Brown et al. 2008; Martins, Baptista et al. 2011; Urrutia, Rubio-Araiz et al. 2013). The same 
pattern of MMPs activity was observed in neuronal and glial cells of different brain regions after 
METH exposure (Mizoguchi, Yamada et al. 2007; Conant, T Lim et al. 2012). Recently, MMP-9 
was demonstrated to degrade occludin and claudin-5 in focal cerebral ischemia and has also 
been shown to alter occludin, claudin-5, and ZO-1 and ZO-2 in early diabetic retinopathy 
(Ramirez, Potula et al. 2009). 
The use of specific MMPs inhibitors (Batimastat, BB-94) effectively prevented the 
decrease in extracellular matrix components expression and reducing the BBB disruption 
induced by METH (Urrutia, Rubio-Araiz et al. 2013). However, the signal transduction pathway 
associated with MMP-9 mediating TJs alterations remains unknown. 
 
2.1.5 Increased oxidative stress 
METH treatment increases excitatory neurotransmission which may result in enhanced 
oxidative stress by producing highly reactive dopamine quinones and ROS (Imam, El-Yazal et 
al. 2001; Mahajan, Aalinkeel et al. 2008; Gold, Kobeissy et al. 2009; Chandramani 
Shivalingappa, Jin et al. 2012; Martins, Burgoyne et al. 2013; Toborek M., Seelbach et al. 
2013).  
The evidence shows that METH increases oxidative stress in cultured ECs, which leads 
to activation of signaling cascades resulting in loss of BBB integrity (Ramirez, Potula et al. 2009; 
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Martins, Burgoyne et al. 2013). Moreover, this increase in oxidative stress results in 
cytoskeleton re-arrangements and redistribution of TJs proteins (Mahajan, Aalinkeel et al. 
2008). Recent data indicated that activation of NADPH oxidase (NOX) is an important source of 
ROS production in brain ECs exposed to METH (Toborek M., Seelbach et al. 2013). In those 
conditions, METH exposure induces a pro-oxidant environment quantified by the increase in 
p66Sch, p47 and gp91 and reduces glutathione levels, as described by Toborek et al, 2013. 
BBB permeability changes induced by oxidative stress can be mediated by Ras and/or Rho 
signaling acting on TJs. These pathways were demonstrated to play important roles in the 
regulation of claudin-5, ZO-1, and ZO-2 expression as well as on BBB assembly (Toborek M., 
Seelbach et al. 2013). On the other hand, results from Martins T et al, 2013, showed that 
METH-induced increased permeability at the BBB involves endothelial Nitric Oxyde Synthase 
(eNOS) activation and NO generation (Martins, Burgoyne et al. 2013). In fact, eNOS is the main 
NOS system regulating barrier function and permeability, controlling also other relevant 
functions such as angiogenesis and inflammatory processes (Fukumura, Gohongi et al. 2001). 
A similar mechanism was previously described for neuronal dopaminergic toxicity (Imam, El-
Yazal et al. 2001), suggesting these drug targets could be similar in both neurons and ECs.  
 
2.1.6 Posttranslational modifications and signaling cascades activation 
The hypothesis that posttranslational modifications of TJs occludin and claudin-5 
contribute to BBB loss of integrity was considered. The phosphorylation state of occludin 
regulates its association with the cell membrane and barrier permeability, and multiple 
phosphorylation sites have been identified on occludin serine (Ser), threonine (Thr) and 
thyrosine (Tyr) residues (Yamamoto, Ramirez et al. 2008; Rao 2009). Assembly and 
disassembly of TJs are associated with reversible phosphorylation of occludin on Ser and Thr 
residues. Occludin dephosphorylation occurs during the disruption of TJs and phosphorylation 
processes leads to its translocation to cell-cell contacts (Andreeva, Krause et al. 2001; Rao 
2009). Intracellular calcium concentration also seems to impact TJs integrity. In this line of 
evidence, low calcium medium resulted in a rapid reduction of occludin phosphorylation, while 
calcium replacement leads to TJs reassembly (Andreeva, Krause et al. 2001; Rao 2009). 
Phosphorylation of TJs may be dynamically regulated by protein kinases and protein 
phosphatases, where the most feasible are atypical protein kinase C (PKC) isoforms (Andreeva, 
Krause et al. 2001; Yamamoto, Ramirez et al. 2008; Rao 2009) but protein phosphatases such 
as PP2A and PP1 are also implicated (Rao 2009). 
Moreover, it was found that phosphorylation processes modulate occludin interaction 
with ZO proteins. Altogether these data indicate that Tyr-phosphorylation of occludin is clearly 
associated with the disruption of TJs, while Ser/Thr-phosphorylation may be required for the 
assembly of occludin into the TJs complex (Yamamoto, Ramirez et al. 2008; Rao 2009). 
After METH exposure in ECs, an increase in RhoA expression was observed (Mahajan, 
Aalinkeel et al. 2008). Accumulating evidence suggests a role for RhoGTPases in the regulation 
of BBB integrity through TJs posttranslational modifications. In fact, other studies have 
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implicated RhoA in TJs functions (Persidsky, Heilman et al. 2006; Mahajan, Aalinkeel et al. 
2008). Yamamoto M et al, 2008 demonstrated the direct phosphorylation of both claudin-5 and 
occludin by Rho-Associated Protein Kinase (ROCK), which is inhibited by the ROCK-specific 
inhibitor Y27632. Thus, it was suggested that the suppression of ROCK activity with specific 
inhibitors could protect the BBB (Yamamoto, Ramirez et al. 2008). Others proposed that after 
METH exposure, prevention of BBB dysfunction with a ROCK inhibitor occurs through 
prevention in ROS-induced transmigration of PBMC across an in vitro simulation of BBB 
(Mahajan, Aalinkeel et al. 2008). 
There are several molecular pathways that have been involved in METH-induced 
effects on BBB function. METH-induced oxidative stress can trigger the activation of myosin 
light chain kinase (MLCK), resulting in enhanced phosphorylation of RhoA, which is known to be 
associated with loss of TJs integrity (Mahajan, Aalinkeel et al. 2008). Moreover, the increased 
permeability of the brain endothelium observed both in vivo and in vitro after METH exposure 
was also attributed to a significantly decrease in the rate of glucose uptake and in the levels of 
glucose transporter protein-1 (GLUT1) (Abdul Muneer, Alikunju et al. 2011).  
Jun Terminal Kinase 1/2 (JNK1/2) phosphorylation is evident after METH exposure. 
Blockade of JNK1/2 is known to reduce MMP-9 activity along with prevention of BBB 
dysfunction, suggesting that the JNK pathway may be involved in the in vivo effects of METH on 
basal lamina and BBB integrity (Urrutia, Rubio-Araiz et al. 2013). 
Cytoplasmic integrin-linked kinase (ILK) expression plays also a role in MMP 
gelatinolytic activity. ILK binds directly to the cytoplasmic domains of β1 integrin and connects 
integrins to the actin cytoskeleton by interacting with several proteins (such as paxillin and 
parvin) thus coordinating actin organization (Wu and Dedhar 2001; Rosano, Spinella et al. 
2006). There is also evidence that ILK expression stimulates MMP-9 activation, whereas ILK 
silencing inhibits invasion in several carcinomas (Troussard, Costello et al. 2000; Rosano, 
Spinella et al. 2006). ILK overexpression and clustering results in the activation of a variety of 
intracellular signaling processes such as Akt phosphorilation and GSK-3 inhibition, which lead 
to the activation of the transcription factor AP-1 resulting in the MMP-9 potentiation (Troussard, 
Costello et al. 2000; Wu and Dedhar 2001). However, the effects of METH on ILK expression 
were not yet addressed.  
 
2.1.7 Body temperature 
One common reported outcome of METH exposure is hyperthermia, which is also an 
important factor in the mediation of METH toxicity (Albertson, Derlet et al. 1999; Imam, El-Yazal 
et al. 2001; Bowyer, Thomas et al. 2008; Gold, Kobeissy et al. 2009; Krasnova and Cadet 2009; 
ElAli, Urrutia et al. 2012). Recently, changes in body temperature induced by METH exposure 
have also been linked to increased BBB permeability. 
Different experiments have shown that the administration of METH or other 
amphetamine derivatives such as MDMA (ecstasy) led to leakiness of the BBB in vivo (Bowyer 
and Ali 2006; Persidsky, Heilman et al. 2006; Yamamoto and Raudensky 2008). In vivo assays 
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show that METH-induced BBB breakdown appears to be temperature-dependent since the 
magnitude of tracers diffusion into the brain tissue tightly correlate with the hyperthermia 
degree. Moreover, when the increase in temperature is prevented these drugs are no longer 
able to induce BBB disruption at the same extent (Krasnova and Cadet 2009). In agreement, 
moderate BBB dysfunction observed in the caudate and putamen after METH treatment was 
exacerbated by hyperthermia (Bowyer, Thomas et al. 2008). Data strongly suggest that 
hyperthermia facilitates METH-induced ROS production and that increased oxidation of DA is 
associated with neurotoxic effects of METH (Ladenheim, Krasnova et al. 2000; Krasnova and 
Cadet 2009; Downey and Loftis 2014). Morphological changes in epithelial cells of the choroid 
plexus – an important element of the blood-cerebral spinal fluid barrier - also tightly correlate 
with METH-induced hyperthermia and BBB permeability (Sharma and Kiyatkin 2009). However, 
the mechanism leading to the disruption in the BBB was not addressed in these studies. 
However, both pharmacological and genetic manipulations can block METH toxicity 
without influencing the drug-induced thermal responses (Ladenheim, Krasnova et al. 2000; 
Krasnova and Cadet 2009), thus showing that METH-related changes in body temperature are 
just a component of the drug toxicity (Krasnova and Cadet 2009). 
 
 
2.2  Neuroprotection strategies for METH-induced effects 
Several approaches have been tested for the treatment and prevention of METH-
induced dopaminergic neurotoxicity, essentially by the use of antioxidants. Glutathione 
peroxidase (GPx) is an antioxidant enzyme that scavenges various peroxides and protects 
membrane lipids and macromolecules from oxidative damage. Due to METH action over these 
processes GPx has been studied in vitro and in vivo in the context of drug exposure. A study 
reported GPx overexpression in PC12 cells as a protective response against METH cytotoxicity 
(Imam, El-Yazal et al. 2001). Moreover, therapy with selenium and other antioxidants resulted in 
positive clinical responses in various neurodegenerative diseases associated with increased 
oxidative damage (selenium is an essential dietary component for mammals present in the 
active center of GPx). METH-induced dopaminergic toxicity and the generation of peroxynitrite 
were significantly avoided both in vitro and in vivo by selenium supplementation (Imam, El-
Yazal et al. 2001). The natural occurring hormone melatonin acts also as a free radical 
scavenger and antioxidant. In vivo and in vitro studies showed that melatonin is effective in 
protecting nuclear DNA, membrane lipids, and possibly cytosolic proteins from oxidative 
damage thus protecting cells, tissue, and organs. Studies from Itzhak et al, showed that this 
hormone protected the depletion of dopamine and its metabolites in mice after the METH 
administration. Furthermore, in another study from the same author, a pretreatment with 
melatonin provided significant protection against METH-induced generation of peroxynitrite and 
3-nitrotyrosine in mouse striatum (Itzhak, Martin et al. 1998). Other studies found important 
neuroprotective effects using NOS inhibitors and peroxynitrites decomposition catalysts in 
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METH-induced dopaminergic neurotoxicity. Blocking the formation of nitric oxide or 
decomposition of peroxynitrite could potentially provide a therapeutic intervention in METH-
induced dopaminergic neurotoxicity. In this line of evidence, N-acetylcysteine, another 
antioxidant and free radical scavenger, known to increase intracellular glutathione levels, was 
used in a mesencephalic dopaminergic neuronal cell model to counteract glutathione depletion 
caused by METH and to prevent oxidative and nitrative damage (Chandramani Shivalingappa, 
Jin et al. 2012). Moreover, this antioxidant is able to partially reduce autophagy processes 
induced by METH treatment, thus demonstrating that alteration of cellular redox status function 
as a key trigger for several damaging processes (Chandramani Shivalingappa, Jin et al. 2012). 
Other approaches to reduce oxidative damage were also used, such as genetic 
manipulation of target enzymes as valuable tools for METH-damage prevention. In this line of 
evidence, it was shown that METH-induced dopaminergic neurotoxicity is attenuated in mice 
overexpressing superoxide dismutase enzymes like CuZnSOD or MnSOD. Similarly, the same 
authors observed that nNOS knockout mice are also protected against METH-induced 
peroxynitrite generation (Imam, El-Yazal et al. 2001). Other antioxidants such 6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) have been intensively used to protect 
animals and cell models from METH-insult (Ramirez, Potula et al. 2009). 
Acetyl-L-carnitine (ALC) was also proposed as a neuroprotective agent with benefits at 
mitochondrial energetics and function, antioxidant activity, stabilization of membranes, protein 
and gene expression modulation, and enhancement of cholinergic neurotransmission (Jones, 
McDonald et al. 2010). Although the exact mechanisms of ALC action is still poorly explored, 
the next section will highlight some of the benefits of this compound in the brain and how these 
may be applicable in various clinical situations.  
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3. Acetyl-L-Carnitine 
 
L-Carnitine (LC), either absorbed from diet or biosynthesized, is incorporated into the 
total body carnitine pool that comprises both free carnitine and acylcarnitines, which include the 
acetyl ester - ALC. The carnitine pool of a healthy human weighing 70 kg is about 15-20 g 
(Marcovina, Sirtori et al. 2013). The largest body storage sites of this pool (95%) are the skeletal 
and cardiac muscle (Pettegrew, Levine et al. 2000; Marcovina, Sirtori et al. 2013; Onofrj, 
Ciccocioppo et al. 2013). In vivo, ALC is synthesized from L-lysine, L-methionine and vitamin C 
mostly in liver and kidney but also in intestine and brain (Inano, Sai et al. 2003; Jones, 
McDonald et al. 2010; Marcovina, Sirtori et al. 2013; Onofrj, Ciccocioppo et al. 2013). Due to its 
amphiphilic structure, ALC is very mobile through-out the cell (Pettegrew, Levine et al. 2000; 
Jones, McDonald et al. 2010), and its most widely known function is the transport of long-chain 
fatty acids into mitochondria for β-oxidation (Sharma and Black 2009; Onofrj, Ciccocioppo et al. 
2013). Carnitine acetyltransferase (CAT) is located on the inner mitochondrial membrane as 
well as in microsomes and peroxisomes and catalyzes the synthesis of ALC. It enters the 
mitochondrial matrix through an exchange of acylcarnitine/carnitine by carnitine-acylcarnitine 
translocase, as represented in Fig.6. For each acylcarnitine molecule crossing the inner 
mitochondrial membrane, one molecule of carnitine is shuttled out (Onofrj, Ciccocioppo et al. 
2013).  
 
 
 
 
Fig.6 Acetyl-L-carnitine in overall energy metabolism.  (CoASH = Coenzyme A). Adapted from (Pettegrew, 
Levine et al. 2000) 
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The role of carnitine per se goes beyond the oxidation of fatty acids since the coenzyme 
A (CoA)-carnitine relationship is critical for energy metabolism. CoA is required for β-oxidation, 
for the catabolism of several amino acids, for the detoxification of organic acids and xenobiotics 
and for the tricarboxylic acid cycle. Decreased carnitine availability induced a reduction of matrix 
free coenzyme A (CoASH) and a parallel increase of the acyl CoA/CoASH ratio. Consequently, 
not only the oxidation of fatty acids, but also the utilization of carbohydrates, the catabolism of 
several amino acids and the detoxification processes may be impaired (Pettegrew, Levine et al. 
2000; Sharma and Black 2009; Marcovina, Sirtori et al. 2013). Moreover, ALC has a role in the 
terminal part of the Krebs cycle where it also facilitates the mitochondrial respiratory chain, 
acting on complexes I (NADH-reductase ubiquitone) and IV (cytochrome oxidase) (Onofrj, 
Ciccocioppo et al. 2013). Alterations in dietary conditions change carnitine and acylcarnitine 
levels in the body. In humans, fasting and diabetic ketosis induce a delayed decrease in plasma 
carnitine and a rapid increase in both long- and short-chain acylcarnitines, suggesting the 
overall importance of carnitine in maintaining energy homeostasis (Marcovina, Sirtori et al. 
2013).  
Some authors suggested that acetyl moiety of ALC (Fig.7) can be used to acetylate 
amine and hydroxil functional groups in peptides and proteins, and possibly modify their 
structure, function and turnover (Pettegrew, Levine et al. 2000). ALC provides acetyl groups for 
acetylcholine synthesis, exerting a cholinergic effect and optimizing the balance of energy 
processes (Madiraju, Pande et al. 2009; Huang, Liu et al. 2012; Onofrj, Ciccocioppo et al. 
2013). 
 
 
 
 
 
Indeed, ALC has long been reported to affect the cholinergic, serotonergic, 
dopaminergic, glutamatergic and GABAergic systems, but the mechanisms involved were 
mostly unknown (Tolu, Masi et al. 2002). Recently, using 
13
C-ALC, it was demonstrated that the 
Fig.7 Molecular structure of L-carnitine and acetyl-L-carnitine. Acetyl group (arrow) is 
proposed to have a role on protein acetylation.  
Adapted from (Pettegrew, Levine et al. 2000) 
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acetyl moiety of the compound is used as an energy source by both astrocytes and neurons 
being rapidly incorporated into glutamate and GABA synthesis (Scafidi, Fiskum et al. 2010). 
This clarifies the direct involvement of ALC in increased glutamine, glutamate and GABA levels, 
through α-ketoglutarate production, via the tricarboxylic acid cycle. Importantly, biosynthesis of 
both tyrosine and L-tryptophan, as well as DA and 5-HT precursors, involves either a 
transamination reaction with glutamate or the participation of glutamine as an amine donor 
(Stryer 1988), which may explain the action of ALC over monoamine production.  Noteworthy, 
glutamate is also the precursor of glutathione biosynthesis (Griffith and T. 1999), an enzyme 
frequently implicated in the antioxidant properties of ALC administration. 
Thus, ALC can provide high-energy acetyl groups to metabolic pathways improving the 
overall energy status of the brain, to alter neurotransmitters biosynthesis, and also has the 
potential to be involved in modulating proteins and gene expression (Jones, McDonald et al. 
2010; Marcovina, Sirtori et al. 2013). 
 
 
3.1  ALC beneficial effects 
ALC administration has been seen to be beneficial in a number of disorders 
characterized by low carnitine concentrations or impaired fatty acid oxidation, including diabetes 
(Xia, Li et al. 2011; Marcovina, Sirtori et al. 2013), sepsis, and cardiomyopathy (Marcovina, 
Sirtori et al. 2013). ALC is prescribed  for inborn errors of metabolism (Sharma and Black 2009) 
but also for several neurologic disorders such as Alzheimer and Parkinson diseases, stroke or 
drug abuse (Pettegrew, Levine et al. 2000; Marcovina, Sirtori et al. 2013).  
The neuroprotective action of ALC has been described in vitro and in vivo. ALC 
administration has been shown to reduce oxidative stress and mitochondrial alterations 
counteracting neurologic pathologies. The protective effects of ALC are likely to be achieved 
through decreased oxidative stress, improvement of mitochondrial function and increased ATP 
production (Marcovina, Sirtori et al. 2013; Onofrj, Ciccocioppo et al. 2013). Although its 
antioxidant role has been reported in numerous studies, carnitine and its esters are devoid of 
direct antioxidant properties. Therefore, other mechanisms are involved in ALC modulation of 
oxidative stress such as those linked to the positive effects on mitochondrial metabolism and 
function (Marcovina, Sirtori et al. 2013). 
It is known that ALC is able to cross the BBB and is present in high concentrations in 
the brain, so ALC supplementing can feasibly affect brain metabolism (Pettegrew, Levine et al. 
2000; Jones, McDonald et al. 2010; Lee, Choi et al. 2012). In the brain, ALC presents several 
physiological effects including the modulation of brain energy, neurohormones, neurotrophic 
factors, synaptic morphology and chemical neurotransmission (Pettegrew, Levine et al. 2000; 
Inano, Sai et al. 2003; Lee, Choi et al. 2012). Both LC and ALC are transported into the brain in 
a sodium-dependent manner via a high-affinity carnitine transporter, the organic cation/carnitine 
transporter 2 (OCTN2). OCTN2 is present in non-neuronal cells such as astrocytes and 
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especially in brain capillary ECs of human, rat and mouse (Yasuto, Ikumi et al. 2001; Inano, Sai 
et al. 2003; Lee, Choi et al. 2012). Kido Yasuto and collaborators observed that BBB is more 
permeable to ALC than LC, since ALC is more efficiently transported from circulating blood into 
the brain across the BBB. According to this and other studies, immortalized ECs are endowed 
with properties for ALC transport similar to those present in vivo and in primary ECs (Yasuto, 
Ikumi et al. 2001; Lee, Choi et al. 2012).  
Within brain cells ALC can be converted by the reversible enzyme CAT into acetyl-CoA 
and carnitine without ATP utilization (Lee, Choi et al. 2012). In the rat brain, ALC administration 
led to reduced oxidation of glucose and increased glycogen synthesis. Changes in the activities 
of specific enzymes involved in the tricarboxylic acid cycle, electron transport chain and amino 
acid metabolism have also been observed after treatment with ALC (Jones, McDonald et al. 
2010).  
ALC treatment restores the thalamo-cortical system in rats prenatally exposed to 
neurotoxic substances such as ethanol and MPP
+
 (1-methyl-4-phenylpyridinium) solution 
(Virmani, Gaetani et al. 2004), promotes acetylcholine synthesis and release protecting cortical 
neurons from the neurotoxic effects of amyloid fragments and peroxidase (Lee, Choi et al. 
2012). ALC significantly prevented mitochondrial oxidative damage and mtDNA deletion with 
improved expression of respiratory chain components after a 3,4-methylenedioxymetham-
phetamine (MDMA or ecstasy) insult (Alves, Binienda et al. 2009). Moreover, ALC 
administration was reported to ameliorate the spatial memory performance of rats exposed to 
neonatal anoxia (Pettegrew, Levine et al. 2000) as well as learning-memory function in aged 
rats (Goo, Choi et al. 2012). 
In humans, patients suffering from dementia, major depression, painful neuropathies 
and Alzheimer’s disease seem to benefit from ALC administration. ALC was reported to improve 
the clinical status of such patients through restoration of cell membranes, brain energy and/or 
synaptic function (Pettegrew, Levine et al. 2000; Onofrj, Ciccocioppo et al. 2013). 
 Much of the research on the role of carnitine and its esterified derivative ALC, has been 
centered in the metabolism. However, there is a great deal of evidence in the literature to 
support new and multifactorial roles for these compounds. In this sense, in 2000, Pettegrew and 
collaborators suggested that ALC increase in membrane stability could be possibly related with 
ALC interaction with cytoskeletal proteins as well as by posttranslational regulation of such 
proteins. Moreover, it was described a role of ALC on enzymatic activity modulation (Pettegrew, 
Levine et al. 2000), as well as epigenetic modifications (Madiraju, Pande et al. 2009; Huang, Liu 
et al. 2012; Onofrj, Ciccocioppo et al. 2013). 
 
 
3.2  ALC preventive effect on BBB function 
There is growing evidence that through maintaining the endothelium homeostasis is 
possible to reduce the incidence or severity of systemic vascular diseases. Although less 
  
23 
 
explored, protection of the BBB has the potential to delay or prevent the development of 
neurodegenerative states. Several compounds have been studied in order to reach 
neuroprotection, including flavonoids, and other polyphenolic agents, and the cytokine 
erythropoietin. These agents seem to have beneficial effects against in vivo and in in vitro injury, 
at the endothelium level, by reducing the level of eNOS and restoring junctional proteins 
(Abbott, Rönnbäck et al. 2006).  
The majority of treatments mentioned so far is designed to seal up and improve the 
transport function of the BBB. However, another approach consisting in the opening the TJs to 
facilitate drug delivery to the brain, was also subject of relevant research (Abbott, Rönnbäck et 
al. 2006). 
In the last few years several studies were carried out in order to assess ALC effects on 
BBB function. However, the mechanisms underlying the protective features reported are very 
poorly understood. 
Recently, some authors reported a link between glucose deprivation and BBB damage 
due to alcohol and METH exposure both in vivo and in vitro (Rump, Abdul Muneer et al. 2010; 
Abdul Muneer, Alikunju et al. 2011; Abdul Muneer, Alikunju et al. 2011; Abdul Muneer, Alikunju 
et al. 2011; Muneer, Alikunju et al. 2011). In this context, Muneer PM and collaborators 
observed that METH and ethanol-induced inhibition of glucose uptake correlates with a 
reduction in glucose transporter protein expression (GLUT1 in astrocytes and GLUT3 in 
neurons). In those studies, ALC counteracts the effect of alcohol on glucose uptake and glucose 
transporter levels, thus reducing neurotoxicity and neuronal degeneration observed (Muneer, 
Alikunju et al. 2011). Moreover, both alcohol and METH exposure impaired the BBB TJs 
proteins claudin-5, occludin and accessory protein ZO-1 in the brain microvessel, along with 
increased BBB permeability of sodium fluorescein and Evans Blue (Rump, Abdul Muneer et al. 
2010; Abdul Muneer, Alikunju et al. 2011). Again, ALC prevented the adverse effects of those 
neurotoxic agents on glucose uptake, BBB permeability and neuronal degeneration through 
stabilization of glucose uptake and GLUT1 protein level. These authors suggested that ALC 
stabilized glycosylation of GLUT1 protein by donating an acetyl group to glucosamine, 
enhancing the activity of acetylglucosamine in the neurovascular compartment (Rump, Abdul 
Muneer et al. 2010; Abdul Muneer, Alikunju et al. 2011). 
In another study, ALC was shown to significantly minimize the level of alcohol-induced 
iNOS/nitrotyrosine formation in neurons and further prevented NOX protein induction in 
astrocytes and microglia, thereby preventing gliosis in the rat brains exposed to alcohol. These 
findings indicated that ALC, by providing carnitine and acetyl groups, has therapeutic value as 
an antioxidant and/or anti-inflammatory agent. Since ALC is not a direct scavenger of free 
radicals, authors postulate that ALC exerts its antioxidant property by indirect mechanisms such 
as its ability to maintain mitochondrial membrane transition potential (Rump, Abdul Muneer et 
al. 2010). Another plausible mechanism for ALC preventing excessive levels of ROS generation 
is through stabilization of biological antioxidant enzymes and antioxidants such as superoxide 
dismutase (SOD), catalase, or the intracellular levels of glutathione. In this context, it was 
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shown afterwards that ALC stabilization of SOD activity correlates with the preservation of both 
Cu/Zn-SOD1 and Mn-SOD2 protein levels in the human brain ECs, thus preserving brain 
vascular function (Haorah, Floreani et al. 2011). 
 
The side-effects of ALC administration in the body, namely those affecting the liver and 
kidney remain unknown, and care should be taken before prescribe it to healthy individuals. 
Although nothing is currently published concerning ALC toxicity, our previous work shows that 
an acute hepatic injury can occur in ALC-treated mice. Since ALC is already not only in clinical 
use as a therapeutic agent for treatment of neurological diseases, but also extensively used to 
promote weight loss and body building in healthy people, unveiling the ALC molecular 
mechanism is therefore highly relevant.  
 
  
  
25 
 
4. References 
Abbott, N. J. (2013). "Blood-brain barrier structure and function and the challenges for CNS drug delivery." J Inherit 
Metab Dis 36(3): 437-449. 
Abbott, N. J., L. Rönnbäck, et al. (2006). "Astrocyte–endothelial interactions at the blood–brain barrier." Nature Reviews 
Neuroscience 7(1): 41-53. 
Abdul Muneer, P. M., S. Alikunju, et al. (2011). "Inhibitory effects of alcohol on glucose transport across the blood-brain 
barrier leads to neurodegeneration: preventive role of acetyl-L: -carnitine." Psychopharmacology (Berl) 
214(3): 707-718. 
Abdul Muneer, P. M., S. Alikunju, et al. (2011). "Methamphetamine inhibits the glucose uptake by human neurons and 
astrocytes: stabilization by acetyl-L-carnitine." PLoS One 6(4): e19258. 
Abdul Muneer, P. M., S. Alikunju, et al. (2011). "Impairment of brain endothelial glucose transporter by 
methamphetamine causes blood-brain barrier dysfunction." Mol Neurodegener 6: 23. 
Albertson, T. E., R. W. Derlet, et al. (1999). "Methamphetamine and the expanding complications of amphetamines." 
Western Journal of Medicine 170(4): 214. 
Alves, E., Z. Binienda, et al. (2009). "Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-
methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain." 
Neuroscience 158(2): 514-523. 
András, I. E., P. Hong, et al. (2003). "HIV-1 Tat Protein Alters Tight Junction Protein Expression and Distribution in 
Cultured Brain Endothelial Cells." Journal of Neuroscience Research 74: 255-265. 
Andreeva, A. Y., E. Krause, et al. (2001). "Protein kinase C regulates the phosphorylation and cellular localization of 
occludin." J Biol Chem 276(42): 38480-38486. 
Balda, M. S., J. A. Whitney, et al. (1996). "Functional Dissociation of Paracellular Permeability and Transepithelial 
Eletrical Resistance and Disruption of the Apical-Basolateral Intermembrane Diffusion Barrier by Expression 
of a Mutant Tight Junction Membrane Protein." The Journal of Cell Biology 134(4): 1031-1049. 
Booth, R. and H. Kim (2012). "Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB)." Lab on 
a chip 12(10): 1784-1792. 
Bowyer, J. F. and S. Ali (2006). "High doses of methamphetamine that cause disruption of the blood‐brain barrier in 
limbic regions produce extensive neuronal degeneration in mouse hippocampus." Synapse 60(7): 521-532. 
Bowyer, J. F., M. Thomas, et al. (2008). "Brain region-specific neurodegenerative profiles showing the relative 
importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier." Ann N Y Acad Sci 
1139: 127-139. 
Bradbury, M. (1993). "The Blood-Brai Barrier." Experimental Physiology(78): 453-472. 
Brown, R. C., A. P. Morris, et al. (2007). "Tight junction protein expression and barrier properties of immortalized mouse 
brain microvessel endothelial cells." Brain Res 1130(1): 17-30. 
Chandramani Shivalingappa, P., H. Jin, et al. (2012). "N-Acetyl Cysteine Protects against Methamphetamine-Induced 
Dopaminergic Neurodegeneration via Modulation of Redox Status and Autophagy in Dopaminergic Cells." 
Parkinsons Dis 2012: 424285. 
Chen, F., T. Hori, et al. (2011). "Occludin is regulated by epidermal growth factor receptor activation in brain endothelial 
cells and brains of mice with acute liver failure." Hepatology 53(4): 1294-1305. 
Conant, K., I. Lonskaya, et al. (2011). "Methamphetamine-associated cleavage of the synaptic adhesion molecule 
intercellular adhesion molecule-5." J Neurochem 118(4): 521-532. 
Conant, K., S. T Lim, et al. (2012). "Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the 
pathogenesis of CNS dysfunction with HIV and methamphetamine." Current HIV research 10(5): 384-391. 
Crime, U. N. O. o. D. a. (2014). World Drug Report 2014. New York, United Nations publication, Sales No. E.14.XI.7. 
Deli, M. (2007). "Blood–brain barrier models." Handbook of Neurochemistry and Molecular Neurobiology: Neural 
Membranes and Transport: 29-55. 
Downey, L. A. and J. M. Loftis (2014). "Altered energy production, lowered antioxidant potential, and inflammatory 
processes mediate CNS damage associated with abuse of the psychostimulants MDMA and 
methamphetamine." Eur J Pharmacol 727: 125-129. 
ElAli, A., A. Urrutia, et al. (2012). "Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters 
ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication." Stroke 43(6): 1647-1653. 
Friend, D. M. and K. A. Keefe (2013). "Glial reactivity in resistance to methamphetamine-induced neurotoxicity." J 
Neurochem 125(4): 566-574. 
Forster, C., M. Burek, et al. (2008). "Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an 
in vitro model of the human blood-brain barrier." J Physiol 586(7): 1937-1949. 
Fukumura, D., T. Gohongi, et al. (2001). "Predominant role of endothelial nitric oxide synthase in vascular endothelial 
growth factor-induced angiogenesis and vascular permeability." Proc Natl Acad Sci U S A 98(5): 2604-2609. 
Furuse, M., T. Hirase, et al. (1993). "Occludin: a novel integral membrane protein localizing at tight junctions." The 
Journal of Cell Biology 123(6): 1777-1788. 
Gold, M. S., F. H. Kobeissy, et al. (2009). "Methamphetamine- and trauma-induced brain injuries: comparative cellular 
and molecular neurobiological substrates." Biol Psychiatry 66(2): 118-127. 
Goncalves, J., S. Baptista, et al. (2010). "Methamphetamine-induced neuroinflammation and neuronal dysfunction in the 
mice hippocampus: preventive effect of indomethacin." Eur J Neurosci 31(2): 315-326. 
Goo, M. J., S. M. Choi, et al. (2012). "Protective effects of acetyl-L-carnitine on neurodegenarative changes in chronic 
cerebral ischemia models and learning-memory impairment in aged rats." Arch Pharm Res 35(1): 145-154. 
Griffith, O. W. and M. R. T. (1999). "The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase." Adv 
Enzymol Relat Areas Mol Biol. 73(209). 
Haorah, J., N. A. Floreani, et al. (2011). "Stabilization of superoxide dismutase by acetyl-l-carnitine in human brain 
endothelium during alcohol exposure: novel protective approach." Free Radic Biol Med 51(8): 1601-1609. 
Haorah, J., B. Knipe, et al. (2005). "Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier 
dysfunction." J Leukoc Biol 78(6): 1223-1232. 
Hawkins, B. T. and T. P. Davis (2005). "The blood-brain barrier/neurovascular unit in health and disease." Pharmacol 
Rev 57(2): 173-185. 
  
26 
 
Huang, H., N. Liu, et al. (2012). "L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in 
vivo and in vitro." PLoS One 7(11): e49062. 
Imam, S. Z., J. El-Yazal, et al. (2001). "Methamphetamine‐Induced Dopaminergic Neurotoxicity: Role of Peroxynitrite 
and Neuroprotective Role of Antioxidants and Peroxynitrite Decomposition Catalysts." Ann N Y Acad Sci 
939(1): 366-380. 
Inano, A., Y. Sai, et al. (2003). "Acetyl‐L‐carnitine permeability across the blood–brain barrier and involvement of 
carnitine transporter OCTN2." Biopharmaceutics & drug disposition 24(8): 357-365. 
Itzhak, Y., J. L. Martin, et al. (1998). "Effect of melatonin on methamphetamine-and 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral 
sensitization." Neuropharmacology 37(6): 781-791. 
Jin, C. H., T. T. Moo, et al. (2002). "Methamphetamine-induced Apoptosis in a CNS-derived Catecholaminergic Cell 
Line." Molecules and Cells 13(2): 221-227. 
Jones, L. L., D. A. McDonald, et al. (2010). "Acylcarnitines: role in brain." Prog Lipid Res 49(1): 61-75. 
Kashiwamura, Y., Y. Sano, et al. (2011). "Hydrocortisone enhances the function of the blood-nerve barrier through the 
up-regulation of claudin-5." Neurochem Res 36(5): 849-855. 
Krasnova, I. N. and J. L. Cadet (2009). "Methamphetamine toxicity and messengers of death." Brain Res Rev 60(2): 
379-407. 
Ladenheim, B., I. N. Krasnova, et al. (2000). "Methamphetamine-induced neurotoxicity is attenuated in transgenic mice 
with a null mutation for interleukin-6." Molecular pharmacology 58(6): 1247-1256. 
Lee, N. Y., H. O. Choi, et al. (2012). "The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine 
transport through the blood-brain barrier." Neurochem Res 37(7): 1499-1507. 
Liebner, S., U. Kniesel, et al. (2000). "Correlation of tight junction morphology with the expression of tight junction 
proteins in blood-brain barrier endothelial cells." Eur J Cell Biol 79(10): 707-717. 
Liu, Y., S. Brown, et al. (2008). "Relationship between methamphetamine exposure and matrix metalloproteinase 9 
expression." Neuroreport 19(14): 1407-1409. 
Ma, J., J. Wan, et al. (2014). "Methamphetamine induces autophagy as a pro-survival response against apoptotic 
endothelial cell death through the Kappa opioid receptor." Cell Death Dis 5: e1099. 
Madiraju, P., S. V. Pande, et al. (2009). "Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone 
acetylation." Epigenetics 4(6): 399-403. 
Mahajan, S. D., R. Aalinkeel, et al. (2012). "Suppression of MMP-9 expression in brain microvascular endothelial cells 
(BMVEC) using a gold nanorod (GNR)-siRNA nanoplex." Immunol Invest 41(4): 337-355. 
Mahajan, S. D., R. Aalinkeel, et al. (2008). "Methamphetamine alters blood brain barrier permeability via the modulation 
of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse." Brain Res 
1203: 133-148. 
Marcovina, S. M., C. Sirtori, et al. (2013). "Translating the basic knowledge of mitochondrial functions to metabolic 
therapy: role of L-carnitine." Translational Research 161(2): 73-84. 
Marshall, J. F. and S. J. O'Dell (2012). "Methamphetamine influences on brain and behavior: unsafe at any speed?" 
Trends Neurosci 35(9): 536-545. 
Martins, T., S. Baptista, et al. (2011). "Methamphetamine transiently increases the blood-brain barrier permeability in the 
hippocampus: role of tight junction proteins and matrix metalloproteinase-9." Brain Res 1411: 28-40. 
Martins, T., T. Burgoyne, et al. (2013). "Methamphetamine-induced nitric oxide promotes vesicular transport in blood-
brain barrier endothelial cells." Neuropharmacology 65: 74-82. 
Masahiko, I., M. Kazumasa, et al. (1999). "Characterization of ZO-2 as a MAGUK Family Member Associated with Tight 
as well as Adherens Junctions with a Binding Affinity to Occludin and a Catenin." J Biol Chem 274(26): 5981-
5986. 
Matthias, B., H. A. M, et al. (2004). "RhoA, Rac 1, and Cdc42 exert distinct effects on epithelial barrier via selective 
strictural and biochemical modulation on junctional proteins and F-actin." Am J Physiol Cell Physiol 287: 
C327-C335. 
Melega, W. P., A. K. Cho, et al. (2007). "Methamphetamine Blood Concentrations in Human Abusers: Application to 
Pharmacokinetic Modeling." Synapse(61): 216–220. 
Mirecki, A., P. Fitzmaurice, et al. (2004). "Brain antioxidant systems in human methamphetamine users." J Neurochem 
89(6): 1396-1408. 
Mizoguchi, H. and K. Yamada (2013). "Roles of matrix metalloproteinases and their targets in epileptogenesis and 
seizures." Clin Psychopharmacol Neurosci 11(2): 45-52. 
Mizoguchi, H., K. Yamada, et al. (2007). "Reduction of methamphetamine-induced sensitization and reward in matrix 
metalloproteinase-2 and -9-deficient mice." J Neurochem 100(6): 1579-1588. 
Muneer, P. A., S. Alikunju, et al. (2011). "Ethanol impairs glucose uptake by human astrocytes and neurons: protective 
effects of acetyl-L-carnitine." International journal of physiology, pathophysiology and pharmacology 3(1): 48. 
Muneer, P. M. A., S. Alikunju, et al. (2011). "Inhibitory effects of alcohol on glucose transport across the blood-brain 
barrier leads to neurodegeneration: preventive role of acetyl-L: -carnitine." Psychopharmacology (Berl) 
214(3): 707-718. 
Navarro-Costa, P., C. E. Plancha, et al. (2012). Citoesqueleto: composição, organização e significado funcional. 
Biologia Celular e Molecular. Lidel. Lisboa: 286-300. 
Northrop, N. A. and B. K. Yamamoto (2012). "Persistent neuroinflammatory effects of serial exposure to stress and 
methamphetamine on the blood-brain barrier." J Neuroimmune Pharmacol 7(4): 951-968. 
O'Shea, E., A. Urrutia, et al. (2014). "Current preclinical studies on neuroinflammation and changes in blood-brain 
barrier integrity by MDMA and methamphetamine." Neuropharmacology. 
Omidi, Y., L. Campbell, et al. (2003). "Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, 
as an in vitro blood–brain barrier model for drug uptake and transport studies." Brain Res 990(1-2): 95-112. 
Onofrj, M., F. Ciccocioppo, et al. (2013). "Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral 
nervous system and beyond." Expert review of neurotherapeutics 13(8): 925-936. 
Park, M., H. J. Kim, et al. (2013). "Methamphetamine-induced occludin endocytosis is mediated by the Arp2/3 complex-
regulated actin rearrangement." J Biol Chem 288(46): 33324-33334. 
Pasquali, L., G. Lazzeri, et al. (2008). "Role of autophagy during methamphetamine neurotoxicity." Ann N Y Acad Sci 
1139: 191-196. 
  
27 
 
Persidsky, Y., D. Heilman, et al. (2006). "Rho-mediated regulation of tight junctions during monocyte migration across 
the blood-brain barrier in HIV-1 encephalitis (HIVE)." Blood 107(12): 4770-4780. 
Pettegrew, J., J. Levine, et al. (2000). "Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: 
relevance for its mode of action in Alzheimer's disease and geriatric depression." Molecular Psychiatry 5: 616-
632. 
Ramirez, S. H., R. Potula, et al. (2009). "Methamphetamine disrupts blood-brain barrier function by induction of 
oxidative stress in brain endothelial cells." J Cereb Blood Flow Metab 29(12): 1933-1945. 
Rao, R. (2009). "Occludin phosphorylation in regulation of epithelial tight junctions." Ann N Y Acad Sci 1165: 62-68. 
Reynolds, J. L., S. D. Mahajan, et al. (2011). "Methamphetamine and HIV-1 gp120 effects on lipopolysaccharide 
stimulated matrix metalloproteinase-9 production by human monocyte-derived macrophages." Immunol Invest 
40(5): 481-497. 
Rosano, L., F. Spinella, et al. (2006). "Integrin-linked kinase functions as a downstream mediator of endothelin-1 to 
promote invasive behavior in ovarian carcinoma." Mol Cancer Ther 5(4): 833-842. 
Roux, F. and P.-O. Couraud (2005). "Rat Brain Endothelial Cell Lines for the Study of Blood–Brain Barrier Permeability 
and Transport Functions." Cellular and Molecular Neurobiology 25(1): 41-57. 
Rump, T. J., P. M. Abdul Muneer, et al. (2010). "Acetyl-L-carnitine protects neuronal function from alcohol-induced 
oxidative damage in the brain." Free Radic Biol Med 49(10): 1494-1504. 
Scafidi, S., G. Fiskum, et al. (2010). "Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the 
immature rat brain." J Neurochem 114(3): 820-831. 
Schrade, A., H. Sade, et al. (2012). "Expression and localization of claudins-3 and -12 in transformed human brain 
endothelium." Fluids Barriers CNS 9: 6. 
Sharma, H. S. and E. A. Kiyatkin (2009). "Rapid morphological brain abnormalities during acute methamphetamine 
intoxication in the rat: an experimental study using light and electron microscopy." J Chem Neuroanat 37(1): 
18-32. 
Sharma, S. and S. M. Black (2009). "Carnitine homeostasis, mitochondrial function and cardiovascular disease." Drug 
Discovery Today: Disease Mechanisms 6(1): e31-e39. 
Singh, A. B. and R. C. Harris (2004). "Epidermal growth factor receptor activation differentially regulates claudin 
expression and enhances transepithelial resistance in Madin-Darby canine kidney cells." J Biol Chem 279(5): 
3543-3552. 
Stryer (1988). Biosinthesys of Amino Acids and Heme. Biochemistry. New York, Ed. W.H. Freeman and Company. 
Takeshita, Y., B. Obermeier, et al. (2014). "An in vitro blood-brain barrier model combining shear stress and endothelial 
cell/astrocyte co-culture." J Neurosci Methods 232: 165-172. 
Toborek M., M. J. Seelbach, et al. (2013). "Voluntary exercise protects against methamphetaminbe-induced oxidative 
stress in brain microvasculature and disruption of the blood-brain-barrier." Molecular Neurodegeneration 
8(22). 
Tolu, P., F. Masi, et al. (2002). "Effects of long-term acetyl-L-carnitine administration in rats: I. increased dopamine 
output in mesocorticolimbic areas and protection toward acute stress exposure." Neuropsychopharmacology 
27(3): 410-420. 
Troussard, A. A., P. Costello, et al. (2000). "The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 
transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)." Oncogene 19: 5444-
5452. 
Urrutia, A., A. Rubio-Araiz, et al. (2013). "A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-
brain barrier induced by methamphetamine." Neurobiol Dis 50: 49-58. 
Virmani, A., F. Gaetani, et al. (2004). "Role of Mitochondrial Dysfunction in Neurotoxicity of MPP:+: Partial Protection of 
PC12 Cells by Acetyl‐l‐Carnitine." Ann N Y Acad Sci 1025(1): 267-273. 
Visse, R. and H. Nagase (2003). "Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, 
function, and biochemistry." Circ Res 92(8): 827-839. 
Wu, C. and S. Dedhar (2001). "Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of 
extracellular matrix to actin cytoskeleton and signaling complexes." J Cell Biol 155(4): 505-510. 
Xia, Y., Q. Li, et al. (2011). "L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by 
improving mitochondrial function." Diabetol Metab Syndr 3: 31. 
Yamamoto, B. K. and J. Raudensky (2008). "The role of oxidative stress, metabolic compromise, and inflammation in 
neuronal injury produced by amphetamine-related drugs of abuse." J Neuroimmune Pharmacol 3(4): 203-217. 
Yamamoto, M., S. H. Ramirez, et al. (2008). "Phosphorylation of claudin-5 and occludin by rho kinase in brain 
endothelial cells." Am J Pathol 172(2): 521-533. 
Yasuto, K., T. Ikumi, et al. (2001). "Functional relevance of carnitine transporter OCTN2 to brain distribution of L-
carnitine and acetyl-L-carnitine across the blood-brain barrier." J Neurochem 79: 959-969. 
Zoia, M., P. D. L, et al. (2000). "Occludin 1B, a Variant of the Tight Junction Protein Occludin." Molecular Biology of the 
Cell 11: 627-634. 
 
 
 
  
 
 
  
  
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOALS 
 
  
  
  
31 
 
 
GOALS  
 
The present work aims to explore the mechanisms by which METH-exposure may lead 
to increased permeability at BBB level, and evaluate the potential of ALC to counteract METH-
induced damage. To do so, we have defined the following steps: 
 
1- Investigate early changes in gene expression after METH exposure using a gene 
array suitable to evaluate cytoskeleton-mediated permeability, to identify research 
targets. This will be achieved by: 
a. Assessing in vivo gene expression of METH-treated mice, using a specific 
array containing the 84 members of PI3K-AKT signaling pathway; 
b. Defining which pathways are interesting enough to deserve further study in 
the context on METH-induced permeability; 
c. Validating the array through the individual analysis of particular genes of 
interest in all treatment conditions. 
 
2- Considering the target genes selected above, assess METH-triggered effects on 
BBB structure/function using and in vitro endothelial cell model exposed to ranging 
doses of METH. The following parameters will be evaluated: 
a. TJs expression and localization; 
b. Actin and tubulin cytoskeleton arrangement; 
c. Evaluation of specific molecular targets within the pathways previously 
selected. 
 
3- Unveiling the effects of ALC in preventing METH-induced BBB dysfunction using 
the same in vitro model: 
a. Pretreat cells with ALC before METH exposure in order to: 
i. Assess the ALC protective effects in preventing METH-induced 
disorganization of cytoskeleton elements; 
ii. Assess the ALC protective mechanism in preventing METH-
triggered activation of specific pathways, comparing when possible 
with other therapeutic approaches. 
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CHAPTER I 
Gene expression after METH exposure in vivo 
(unpublished work)
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“The scientist is motivated primarily by curiosity and a desire for truth.” 
Irving Langmuir
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1. Introduction 
There is growing evidence that illicit drugs such as METH exert substantial 
transcriptional and epigenetic modifications in the brain (Betts, Krasnova et al. 2002; Martin, 
Jayanthi et al. 2012; Cadet, Jayanthi et al. 2013). Gene expression is regulated by epigenetic 
modifications, which are intimately involved in the development and clinical course of many 
neurological diseases, such as addiction. In that sense, it was already shown that METH might 
trigger transcriptional and epigenetic changes that are specific to this drug (Cadet, Jayanthi et 
al. 2013).  
Based on the previously described effects of METH, it is important to address gene 
expression involvement in the regulation of neuronal responses to stimuli, particularly those that 
may be implicated in the neuronal responses underlying drug addiction and abuse. In the brain, 
METH effects are particularly prominent in the striatum, a basal ganglia involved in drug-taking 
behaviors (Chang, Alicata et al. 2007; Volz, Fleckenstein et al. 2007).  
The PI3K/AKT pathway is important not only for the development of many diseases but 
also for signaling in several mechanisms in normal cells. This pathway plays an important role in 
numerous cellular functions, such as adhesion, proliferation, differentiation, cellular metabolism, 
and cytoskeletal reorganization, migration, invasion and survival. Moreover, this pathway acts 
though integration of signals like insulin, cytokines, growth factors and environmental stresses, 
mainly for regulating cell proliferation, motility, differentiation and survival (Polivka and Janku 
2014). Recently, some evidences strongly suggested the involvement of PI3K-AKT signaling 
pathway in cytoskeleton-mediated permeability (Bruewer, Hopkins et al. 2004). Since METH 
has been shown to strongly affect both cytoskeleton structure and permeability events 
(Ramirez, Potula et al. 2009; Martins, Baptista et al. 2011; Park, Kim et al. 2013), this pathway 
seems to be to assess METH-induced cytoskeleton and permeability alterations through PI3K-
AKT pathway. 
Here, we aimed to investigate early changes in gene expression after METH exposure, 
through assessing in vivo gene expression of METH-treated mice, using a specific array 
containing the 84 members of PI3K-AKT signaling pathway; and analyzing and correlating 
genes with altered expression that may be involved in METH-related effects. Moreover, we 
intend to construct an interactome using Ingenuity Pathway Analysis (IPA), QIAGEN software. 
To validate the array results, we aim to analyze individually gene expression of selected genes 
in every treatment conditions (saline; METH; ALC; ALC/METH and METH/ALC). 
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2. Material and methods 
2.1 Animal treatment and procedures 
Fifteen C57BL/6 mice were divided into 5 groups of treatment (3 animals per group): 
control saline; METH (3 x 5mg/kg i.p.); METH/ALC (3x5mg/kg i.p., followed by a single i.p. 
administration of 200 mg/kg of ALC, 30 min after); ALC/METH (3x5mg/kg i.p., preceded in 30 
min by a single i.p. administration of 200 mg/kg of ALC), and ALC control. Animals were 
maintained under a 12h dark/light schedule and were given ad libitum food and water access. 
All experiments were performed respecting the Guidelines of the European Union Council 
86/609/EU and 2010/63/EU and the Portuguese law for the care and use of experimental 
animals (DL n°1095/92) at the Animal Facility of the Instituto de Biologia Molecular e Celular 
(IBMC), University of Porto. All efforts were made to minimize animal suffering and to reduce 
the number of animals.  
 
2.2 Brain RNA extraction and RT2 Profiler PCR Array 
Animals were killed 24h after the administration of the different treatments. Brain 
regions were briefly dissected on ice and frozen on dry ice cooled isopentane. Total RNA from 
each brain region was extracted using RNeasy® Mini Kit (Qiagen, Hilden, Germany). A pool of 
RNA from each group was prepared and RNA quality was checked by Experion automated 
electrophoresis system (Bio-Rad Hercules, CA, USA). Synthesis of cDNA was performed by 
Qiagen RT
2
 HT First Strand cDNA kit and a total amount of 2,0 µg of RNA was used to screen 
genes expression of striatum METH-treated animals, compared to control.  
This study was carried out using a RT
2
 Profiler PCR Array plates approach, that takes 
advantage of the combination of real-time PCR performance and the ability of microarrays to 
detect simultaneously the expression of 84 members of PI3K-AKT signaling pathway (# PAMM-
058A). This tool comprises 5 housekeeping genes that enable the normalization of data and 
different internal controls to validate DNA quality. RT
2 
SYBR Green Mastermix is used to amplify 
and quantify genes expression on a cycler (Bio-Rad iQ5 model). Gene relative expression was 
calculated using CT method, expressed as relative fold change to the control saline treated 
animals. Gene expression of selected target genes was assessed by traditional RT-PCR and 
analyzed individually in every treatment conditions. 
 
2.3 Real Time PCR 
RT
2
 SYBR Green Mastermix was used to amplify and quantify genes expression on a 
cycler (Bio-Rad iQ5 model), using a total amount of 2.0 µg of RNA from striatum animals, in 
every treatment conditions. Specific primers were designed using Beacon software for gene 
relative expression and the respective sequences are represented in Table 1. 
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Data were analyzed by CT method after normalization to housekeeping gene 
expression of Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) and Beta-Glucuronidase 
(GUSB). 
 
Table 1 – Primers sequences obtained from Beacon software 
Gene Forward sequence (5’-3’) Reverse sequence (5’-3’) 
IGF1 GCTATGGCTCCAGCATTCG GCTCCGGAAGCAACACTCA 
IGF1R GGACTGTTCAACGGTAGG GCTTAGGACTTGGCATCATA 
ILK TGAATGAGCACGGCAATG TTGTCCACAGGCATCTCT 
MMP2 TACTCTGGAGCGAGGATA GATGTATGTCTTCTTGTTCTTACT3 
MMP9 GTCCAACTCACTCACTGT TCTGACCTGAACCATAACG 
RHOA GCTTGCTCATAGTCTTCAG CAGGCGGTCATAATCTTC 
RAC1 GGACAAGAAGATTATGACAGAT ACGAGGATGATAGGAGTATT 
GAPDH ACCTGCCAAGTATGATGA GGAGTTGCTGTTGAAGTC 
GUSB GGTGAAGGTGACAACAACT CTGAATCCTCGTGCTTATTGA 
 
 
2.4 Software analysis and interactome construction 
Based on the information provided by RT
2
 Profiler PCR Array plates the Network 
Analysis tool of a trial version of IPA software was used in order to assess genes interaction. 
The interactome construction was done using databases scientific information about mouse 
brain only. 
 
2.5 Statistical analysis 
Results from RT-PCR were represented as mean±SEM. Statistical analysis was 
performed by one-way ANOVA followed by the Sidak’s post hoc test. When data normality was 
not verified, the Kruskal Wallis test was used. Significance was set at p<0.05. All analysis were 
conducted using the software GraphPad Prism® 6.0 (GraphPad Software, La Jolla CA). 
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3. Results and Discussion 
3.1 PCR Array for in vivo gene expression after METH exposure 
Among the 84 genes analyzed the relative expression of 24 of them is altered in METH-
treated animals when compared to the control, as shown in Table 2.  
Table 2. Gene expression after METH-exposed mice assessed through RT
2
 Profiler PCR Array 
Genbank Symbol Gene name 
2
-ΔCt
 
Fold 
Regulation 
METH 
group 
Saline 
group 
METH/ 
Saline 
NM_019655 ADAR Adenosine deaminase, RNA-specific 1,7E-01 1,8E-01 -1,04 
NM_009652 AKT1 Thymoma viral proto-oncogene 1 5,1E-01 4,2E-01 1,22 
NM_007434 AKT2 Thymoma viral proto-oncogene 2 9,0E-01 4,9E-01 1,84 
NM_011785 AKT3 Thymoma viral proto-oncogene 3 9,2E-02 5,0E-02 1,86 
NM_007462 APC Adenomatosis polyposis coli 4,8E-01 2,9E-01 1,62 
NM_007522 BAD BCL2-associated agonist of cell death 1,9E-01 1,6E-01 1,16 
NM_013482 BTK Bruton agammaglobulinemia tyrosine kinase 6,2E-03 5,1E-03 1,22 
NM_015733 CASP9 Caspase 9 8,6E-02 9,5E-02 -1,10 
NM_007631 CCND1 Cyclin D1 4,6E-02 2,0E-02 2,29 
NM_009841 CD14 CD14 antigen 2,5E-02 1,4E-02 1,73 
NM_009861 CDC42 Cell division cycle 42 homolog (S. cerevisiae) 5,0E-01 3,9E-01 1,26 
NM_009875 CDKN1B Cyclin-dependent kinase inhibitor 1B 2,1E-01 4,7E-02 4,37 
NM_007700 CHUCK Conserved helix-loop-helix ubiquitous kinase 3,6E-01 1,8E-01 2,02 
NM_007788 CSNK2α1 Casein kinase 2, α 1 polypeptide 8,9E-01 9,7E-01 -1,09 
NM_007614 CTNNβ1 Catenin (cadherin associated protein), β 1 6,1E-01 6,4E-01 -1,04 
NM_011163 EIF2αK2 Eukaryotic translation initiation factor 2-α  kinase 2 4,0E-02 3,7E-02 1,07 
NM_145625 EIF4B Eukaryotic translation initiation factor 4B 2,0E-01 2,8E-02 7,00 
NM_007917 EIF4E Eukaryotic translation initiation factor 4E 9,2E-01 8,0E-01 1,16 
NM_007919 EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 6,4E-03 1,2E-02 -1,90 
NM_001005331 EIF4ɣ1 Eukaryotic translation initiation factor 4, ɣ 1 6,2E-01 6,4E-01 -1,03 
NM_007922 ELK1 ELK1, member of ETS oncogene family 4,9E-02 1,6E-02 2,96 
NM_010177 FAS1 Fas ligand (TNF superfamily, member 6) 5,6E-03 4,8E-03 1,17 
NM_008019 FKBP1α FK506 binding protein 1ª 4,3E+00 3,5E+00 1,23 
NM_010234 FOS FBJ osteosarcoma oncogene 1,9E-01 6,3E-02 3,01 
NM_019739 FOXO1 Forkhead box O1 4,7E-01 7,0E-02 6,69 
NM_019740 FOXO3 Forkhead box O3 3,7E-01 5,5E-01 -1,48 
NM_020009 MTOR FK506 binding protein12-rapamycin associated protein 1 1,6E-01 1,6E-01 -1,03 
NM_010288 GJA1 Gap JUNction protein, α  1 5,0E-01 6,8E-01 -1,36 
NM_010345 GRB10 Growth factor receptor bound protein 10 1,7E-01 6,2E-02 2,83 
NM_008163 GRB2 Growth factor receptor bound protein 2 3,7E-01 1,7E-01 2,18 
NM_019827 GSK3β Glycogen synthase kinase 3 β 2,1E-01 2,6E-01 -1,24 
NM_008284 HRAS1 Harvey rat sarcoma virus oncogene 1 2,1E+00 2,5E+00 -1,16 
NM_013560 HSPB1 Heat shock protein 1 2,4E-01 2,6E-01 -1,11 
NM_010512 IGF1 Insulin-like growth factor 9,8E-03 3,3E-02 -3,32 
NM_010513 IGF1R Insulin-like growth factor I receptor 4,3E-02 4,2E-02 1,02 
NM_010562 ILK Integrin linked kinase 4,3E-01 1,8E-01 2,36 
NM_008363 IRAK1 Interleukin-1 receptor-associated kinase 1 5,3E-02 2,4E-02 2,23 
NM_010570 IRS1 Insulin receptor subtrate 1 6,3E-02 9,7E-02 -1,54 
NM_010578 ITGB1 Integrin β 1 (fibronection receptor β) 3,3E-01 5,1E-01 -1,55 
NM_010591 JUN JUN Oncogene 1,8E-02 1,6E-01 -8,85 
NM_008927 MAP2K1 Mitogen-activated protein kinase kinase 1 1,9E+00 1,9E+00 -1,02 
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Genbank Symbol Gene name 
2
-ΔCt
 
Fold 
Regulation 
METH 
group 
Saline 
group 
METH/ 
Saline 
NM_011949 MAPK1 Mitogen-activated protein kinase 1 4,5E+00 3,0E+00 1,50 
NM_011951 MAPK14 Mitogen-activated protein kinase 14 2,7E-01 1,9E-01 1,47 
NM_011952 MAPK3 Mitogen-activated protein kinase 3 4,1E-01 2,1E-01 1,96 
NM_016700 MAPK8 Mitogen-activated protein kinase 8 1,1E-01 3,0E-02 3,73 
NM_010839 MTCP1 Mature T-cell proliferation 1 4,2E-02 2,0E-02 2,08 
NM_010851 MYD88 Myeloid differentiation primary response gene 88 5,6E-03 4,8E-03 1,16 
NM_008689 NFkB1 
Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1, p105 
7,6E-02 3,4E-02 2,20 
NM_010907 NFkBiα 
Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, α  
1,2E-01 1,9E-01 -1,56 
NM_008774 PABPC1 Poly(A) binding protein, cytoplasmic 1 2,1E-01 2,9E-02 7,42 
NM_011035 PAK1 P21 (CDKN1A) -activated kinase 1 4,1E-01 7,9E-01 -1,91 
NM_011058 PDGFRα Platelet derived growth factor receptor, α polypeptide 1,4E-01 9,3E-02 1,55 
NM_172665 PDK1 Pyruvate dehydrogenase kinase, isoenzyme 1 1,3E-01 2,8E-01 -2,15 
NM_133667 PDK2 Pyruvate dehydrogenase kinase, isoenzyme 2 1,2E-02 4,8E-03 2,42 
NM_011062 PDPK1 3-phosphoinositide dependent protein kinase-1 4,5E-01 4,4E-01 1,03 
NM_008839 PIK3Cα Phosphatidylinositol 3-kinase, catalytic, α polypeptide 2,3E-01 1,4E-01 1,62 
NM_020272 PIK3Cɣ Phosphatidylinositol 3-kinase, catalytic, ɣ polypeptide 1,2E-02 5,0E-03 2,32 
NM_001024955 PIK3R1 Pi3k, regulatory subunit, polypeptide 2 (p85 α ) 3,3E-01 3,5E-01 -1,04 
NM_008841 PIK3R2 Pi3k, regulatory subunit, polypeptide 2 (p85 β) 1,0E-01 8,1E-02 1,28 
NM_011101 PRKCα Protein kinase C, α  2,5E-01 3,2E-01 -1,24 
NM_008855 PRKCβ Protein kinase C, β 3,9E+00 3,7E+00 1,08 
NM_008860 PRKCɀ Protein kinase C, ɀ 1,2E+00 1,7E+00 -1,48 
NM_008960 PTEN Phosphatase and tensin homolog 1,2E+00 8,2E-01 1,41 
NM_007982 PTK2 PTK2 protein tyrosine kinase 2 2,0E-01 2,0E-01 -1,00 
NM_011202 PTPN11 Protein tyrosine phosphatase, non-receptor type 11 8,2E-01 7,3E-01 1,13 
NM_009007 RAC1 RAS-related C3 botulinum substrate 1 2,9E+00 1,5E+00 1,96 
NM_029780 RAF1 V-raf-leukemia viral oncogene 1 2,4E-01 3,2E-01 -1,31 
NM_145452 RASA1 RAS p21 protein activator 1 3,4E-01 1,7E-01 1,94 
NM_011250 RBL2 Retinoblastoma-like 2 1,2E-01 3,0E-02 3,89 
NM_053075 RHEB RAS-homolog enriched in brain 5,9E-01 3,4E-01 1,73 
NM_016802 RHOA Ras homolog gene family, member A 5,0E-01 3,5E-01 1,44 
NM_009097 RPS6KA1 Ribosomal protein S6 kinase polypeptide 1 3,6E-02 1,5E-02 2,39 
NM_028259 RPS6kB1 Ribosomal protein S6 kinase polypeptide 1 5,4E-02 4,0E-02 1,35 
NM_011368 SHC1 Src homology2 domain-containing transform.protein C1 3,4E-02 4,0E-02 -1,17 
NM_009231 SOS1 Son of sevenless homolog 1 (Drosophila) 6,6E-02 1,1E-02 6,02 
NM_020493 SRF Serum response factor 1,3E-01 8,7E-02 1,45 
NM_009337 TCL1 T-cell lymphoma breakpoint 1 5,6E-03 4,8E-03 1,17 
NM_054096 TIRAP 
Toll-interleukin 1 receptor (TIR) domain-containing 
adaptor protein 
7,6E-03 6,2E-03 1,23 
NM_021297 TLR4 Toll-like receptor 4 5,6E-03 1,0E-02 -1,82 
NM_023764 TOLLIP Toll interacting protein 5,8E-01 3,4E-01 1,71 
NM_022887 TSC1 Tuberous sclerosis 1 5,3E-02 2,1E-02 2,53 
NM_011647 TSC2 Tuberous sclerosis 2 2,9E-01 2,0E-01 1,47 
NM_028459 WASL Wiskott-Aldrich syndrome-like (human) 4,0E-02 5,1E-02 -1,27 
NM_011738 YWHAH 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide 
1,8E+00 2,4E+00 -1,32 
NM_010368 GUSB Glucuronidase, β 1,2E-01 1,0E-01 1,23 
NM_013556 HPRT1 Hypoxanthine guanine phosphoribosyl transferase 1 2,0E+00 2,8E+00 -1,42 
NM_008302 HSP90αA1 Heat shock protein 90 α , class B member 1 5,3E-02 5,9E-02 -1,11 
NM_008084 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 7,9E+00 6,8E+00 1,15 
NM_007393 ACT b Actin, β 9,9E+00 8,8E+00 1,12 
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We have started by grouping genes with altered expression (shown in Table.3) into 
three main classes according to their function. A group of 12 of those genes exert their function 
regulating cell cycle, transcription and translation processes; 6 genes are implicated on 
signaling processes, mainly those regulating extracellular signals, adapter proteins and surface 
receptors; and 6 genes play an essential role on metabolism. However, some of these genes 
could play different roles in independent pathways, making their categorization into different 
groups more complex. A volcano plot of altered genes is represented in Fig.1.  
 
Table 3. Gene grouping after expression analysis 
Gene 
METH/Control           
Ratio 
Function 
CCND1 Cyclin D1 2,24 
Cell cycle CDKN1B Cyclin-Dependent Kinase Inhibitor 1B 4,26 
RBL2 Retinoblastoma-Like 2 3,79 
        
ELK1 Member Of ETS Oncogene Family 2,89 
Transcription 
FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog 2,93 
FOXO1 Forkhead Box O1 6,52 
JUN Jun Proto-Oncogen (AP-1) -9,08 
NFkB1 Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1 2,16 
CHUCK Conserved helix-loop-helix ubiquitous kinase 2,02 
        
EIF4B Eukaryotic Translation Initiation Factor 4B 6,83 
Translation PABPC1 Poly(A) binding protein, cytoplasmic 1  7,23 
RPS6KA1 Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 1 2,33 
  
 
    
ILK Integrin-Linked Kinase  2,3 
Signaling 
IRAK1 Interleukin-1 Receptor-Associated Kinase 1 2,17 
MTCP1 Mature T-Cell Proliferation 1 2,02 
PIK3Cɣ Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma 2,26 
MAPK8 Mitogen-Activated Protein Kinase 8 (JNK) 3,64 
TSC1 Tuberous Sclerosis 1 2,47 
  
 
    
IGF1 Insulin-Like Growth Factor 1 -3,41 
Metabolism 
GRB2 Growth Factor Receptor-Bound Protein 2 2,13 
GRB10 Growth Factor Receptor-Bound Protein 10 2,76 
PDK1 Pyruvate Dehydrogenase Kinase, Isozyme 1 -2,31 
PDK2 Pyruvate Dehydrogenase Kinase, Isozyme 2 2,36 
SOS1 Son Of Sevenless Homolog 1 (Drosophila) 5,87 
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Fig. 1  Volcano plot representation of gene expression fold change of the 84 members of PI3K-AKT signaling pathway, 
in mice treated with METH. Genes with altered expression are identified. 
 
3.1.1 Cell cycle regulators 
Among cell cycle regulators, cyclin D1 (CCND1), cyclin dependent kinase inhibitor 1B 
(CDKN1B) and retinoblastoma 2 (RBL2) showed important fold changes. CCND1 is a gene that 
encodes for the regulatory subunit of a holoenzyme responsible for the phosphorylation and 
inactivation of retinoblastoma protein (pRb), thus promoting progression through the G1-S 
phase of the cell cycle. CCND1 role on tumorigenesis has been largely explored since it 
regulates proliferation and differentiation (Barré and Perkins 2007; Stein, Milewski et al. 2013). 
Both CDKN1B and RBL2, which are important key players on cell cycle progression/arrest, 
showed an upregulation on METH-treated animals in our study (ckkn1b – 4.37 and RBL2 – 
3.89).  CDKN1B is a classical negative cell cycle regulator that controls the G1/S-phase 
transition by binding to and regulating the activity of cyclin-dependent kinases (Stein, Milewski 
et al. 2013). Interestingly, some studies have explored the importance of CDKN1B in 
metabolism regulation. Experiments using an animal model of insulin resistance (type 2 
diabetes) showed that the deletion of the gene encoding CDKN1B results in ameliorating of 
hyperglycemia through the stimulation of pancreatic β-cell proliferation (Uchida, Nakamura et al. 
2005). In our experiment, we found an upregulation of CDKN1B and a downregulation of 
insulin-like growth factor (IGF1) after METH-exposure. 
There are few studies assessing METH impact on cell cycle (Cadet, Jayanthi et al. 
2013; Baptista, Lasgi et al. 2014; Jackson, Shah et al. 2014). In the context of drug abuse, 
METH has been reported to decrease self-renewal capacity, delaying cell cycle progression in 
neuronal stem cells. In this study of Baptista et al, METH induced a delay in the transition from 
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Go/G1 to the S phase along with a decrease in cyclin E protein expression, but without any 
alteration in both cyclin D1 and cyclin A protein levels (Baptista, Lasgi et al. 2014). However, 
genes of CDK and cyclin family, were already reported to be upregulated after METH exposure 
(Jackson, Shah et al. 2014). 
More recent discoveries point CCND1 as an important regulator of metabolism, cellular 
adhesion and motility (Fu, Wang et al. 2004). Several studies are consistent with a model in 
which CCND1 acts as a key sensor and integrator of extracellular environment signals to the 
core cell cycle machinery (Barré and Perkins 2007), and its activation could be induced by 
growth factors including epithelial growth factor (Egf) and IGF1 and IGF2 (Holnthoner, Pillinger 
et al. 2002; Fu, Wang et al. 2004).  
As well, other effectors like integrin-linked kinase (ILK) are responsible for the increased 
levels of transcription and translation of CCND1 via PI3K/AKT pathway. Otherwise, some 
evidences show that CCND1 has an important role on adhesion, in part mediated by F-actin 
fibers. The fact that CCND1 regulates cellular adhesion dynamics suggest that this protein 
regulates cellular substratum interactions and therefore contributes to the invasiveness and/or 
metastatic phenotype, independently of its effects on cell cycle progression (Fu, Wang et al. 
2004).   
 
 
3.1.2 Transcription and translation regulators 
Another altered gene was IKKα, also known as CHUCK (conserved helix-loop-helix 
ubiquitous kinase). This gene encodes for a protein that belongs to an enzyme complex (IKK) 
that acts upstream of NFκB (the nuclear factor kappa-light-chain-enhancer of activated B cells) 
signal transduction cascade. Through phosphorilation processes, IKK dissociates NFκB which 
migrates to the nucleus and activates the expression of several genes. In the present work, we 
found an upregulation of NFκB1 (a precursor of NFκB). Although NFκB-independent 
mechanisms also exist, many authors have described a role for NFκB subunits and IKK in the 
control of CCND1 expression. This association is evidenced in our study since all these genes 
were upregulated 24h after the administration of METH (CCND1 – 2.29; CHUCK – 2.02; NFκB1 
– 2.20). There are multiple NFκB pathways under the regulation of a large array of stimuli in 
many cell contexts, resulting in functional differences, such as activation or repression of 
specific target genes by the same NFκB. In the brain, a role on memory, plasticity and learning 
has been described (Salles, Romano et al. 2014).  In the context of drug-exposure, there is 
evidence that METH can activate and induce nuclear translocation of NFκB, allowing 
transcription in microglial cells (Wires, Alvarez et al. 2012).  
Besides NFκB, other different genes regulating transcription and translation processes 
were found in METH-treated animals with a fold change of 2 to 7 times greater than the saline 
group. ELK1 (member of ETS oncogene family) is a transcription activator that has an important 
function in events such as long-term memory formation, drug addiction and depression. Some 
studies showed that activation of ELK1 occurred after exposure to drugs of abuse, initiating a 
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gene transcription program that is supposed to lead to the long-term effects of repeated 
exposure to psychostimulants. Moreover, FOS is an immediate early gene, which expression 
occurs immediately after the stimulus. It can cause both gene repression and gene activation 
and is involved in important cellular events like proliferation, survival, differentiation but also 
apoptotic cell death (Burch, Yuan et al. 2004). Our model of METH exposure showed an 
increase in striatal ELK1 and FOS mRNA levels 24h after administration (ELK1 – 2.96; FOS – 
3.01), which is in agreement with the literature reported after drugs of abuse exposure (Betts, 
Krasnova et al. 2002; Salzmann, Marie-Claire et al. 2003; Mizoguchi, Yamada et al. 2004; 
Cadet, Jayanthi et al. 2013). It was reported that Elk-1 and CREB transcription factors, both 
critically involved in immediate-early genes mRNA induction, such as c-FOS, may be 
phosphorylated by ERK after exposure to psychostimulants, being responsible for persistent 
drug-induced plasticity (Salzmann, Marie-Claire et al. 2003; Mizoguchi, Yamada et al. 2004). 
c-JUN is encoded by the JUN gene and binds to FOS to form dimeric complexes (AP-1) 
with high affinity for DNA-binding sites. Both c-JUN and its dimeric partners are subject to 
regulation by diverse extracellular stimuli including pro-inflammatory cytokines, growth factors, 
oxidative stress and UV radiation, among others (Wisdom, Johnson et al. 1999; Burch, Yuan et 
al. 2004). Although the response to the stimulus could be initially different, evidence shows that 
they all regulate c-JUN through the activation of MAPK (Mitogen-Activated Protein Kinase) 
members, as is the case of MAPK8. Functional data suggest that c-JUN is not merely a target of 
activation by extracellular stimuli. Instead, it plays a role in mediating the cellular response. Two 
important biological processes implicate JUN activity: the regulation of cell cycle progression 
and the anti-apoptotic response. The regulation of c-JUN is complex and distinct biochemical 
mechanisms underlie its different cellular functions. Concerning cell cycle regulation, c-JUN has 
the ability to mediate G1 progression by a direct control of CCND1. Cooperating with NFκB, c-
JUN protects cells from UV irradiation but it requires proper phosphorilation of specific serines 
(Wisdom, Johnson et al. 1999). Although the striatal JUN mRNA levels were found unaltered 
after chronic METH administration (Cadet, McCoy et al. 2009; Saint-Preux, Bores et al. 2013), 
our acute exposure significantly decreased JUN gene expression (-8.85), while increasing 
MAPK8 expression (3.73). The biological significance of change remains unknown, essentially 
because JUN effects seem to be context-dependent and MAPK8 could be activated through 
different stimulus. Wisdom et al proposed that c-JUN could induce the expression of genes that 
block apoptosis (Wisdom, Johnson et al. 1999), therefore, c-Jun downregulation may be 
associated with METH-induced apoptotic events. In accordance, Chetswang et al observed an 
increased phosphorilation of c-JUN, hypothesizing that this process is responsible for the Bax 
and Bcl2 expession, leading to apoptotic death (Chetsawang, Suwanjang et al. 2012). However, 
different reports show opposite roles for JUN which could mean that the cell-context may 
determine the outcome of that gene change. 
Forkhead Box Protein O1 (Foxo1) is a protein encoded by the gene FOXO1. Foxo1 is a 
transcription factor involved in the regulation of gluconeogenesis and glycogenolysis by insulin 
signaling playing also a central role on adipogenesis process. Foxo1 transcriptional activity is 
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dependent on its phosphorylation state, since this protein is regulated through phosphorylation 
(Sasaki and Kitamura 2009). In fact, evidence on hepatocarcinomas shows that an 
overexpression of IGF-1 decreases the phosphorylation levels of proteins like Foxo1, Akt and 
p70S6K (Hernandez-Breijo, Monserrat et al. 2013). However, the effect of FOXO1 upregulation 
(6.69) and a downregulation of IGF-1 (-3.32) at the brain level remains unveiled. 
Concerning translation regulators, in our experiment both PABPC1 (polyadenylate 
binding protein 1) and EIF4B (Eukaryotic Translation Initiation Factor 4B) showed gene 
expression upregulation 24h after METH administration. Both PABPC1 and EIF4B are genes 
that encode for proteins that regulate and initiate the translation processes. PABPC1 is required 
for poly(A) shortening and translation initiation and interacts with Eif4 family members that 
regulate mRNA strand binding to ribosomes (Khan and Goss 2012). The upregulation of these 
two genes (PABPC1 – 7.42; EIF4B – 7.00) could simply mean that cell machinery is active after 
the drug stimulus, responding with genetic expression and protein synthesis. 
 
3.1.3 Metabolism players 
Growth factors such as EGF, IGF and platelet-derived growth factor (PDGF) and 
hormone insulin, play a role on mTOR Complex1 regulation through PI3K signaling pathway. 
The interaction of insulin with the tyrosine kinase receptor leads to the phosphorylation of the 
receptor, creating on the cell membrane sites for the recruitment of IRS1 (Insulin Receptor 
Substrate 1) and IRS2 (Insulin Receptor Substrate 2). In turn, specific phosphorylated residues 
in IRS1 and/or IRS2 function as recognition motifs for the binding of key signaling molecules, 
such as class I PI3K. This interaction will result in the production of PtdIns (3,4,5)P3 second 
messengers that bind molecules including PKB/Akt and phosphoinositide-dependent kinase 1 
(PDK1). If PtdIns (3,4,5)P3 binds to PDK1, S6k1 is recruited and phosphorylated both by PDK1 
and mTOR Complex2. In turn, activated PKB/Akt has several downstream substrates including 
glycogen synthase kinase-3 (GSK3), FOXO transcription factors and TSC2 of the TSC1–TSC2 
complex, which acts as a tumor suppressor complex. TSC2 activation results in its dissociation 
and degradation of the complex, which releases the small GTPase RAS homologue enriched in 
brain (RHEB) from the inhibitory state into the GTP-bound active state. It is believed that active 
RHEB enables mTOR Complex1 signaling to downstream substrates, such as S6K1. When that 
pathway is activated by growth factors, PKB/Akt can mediate the phosphorylation of several 
specific substrates, not only those described above, but also caspase 9 and the BCL-2-
antagonist of cell death (BAD), culminating in a prosurvival response. Moreover, PTEN 
(Phosphatase and Tensin Homolog) is a negative regulator of this step and converts 
PtdIns(3,4,5)P3 into PtdIns(4,5)P2, resulting in a reduced recruitment of PKB/Akt to the cell 
membrane (Dann, Selvaraj et al. 2007). 
In the present study, caspase 9 was seen overexpressed nor PTEN, S6K1 or IRS1 
gene expression was altered. Moreover, and in accordance with the observed decreased fold 
change of PDK1 (-2.15) and more important, IGF-1 downregulation (-8.85), it could mean that 
insulin pathway is compromised under METH exposure. However, using positron emission 
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tomography (PET) we evaluated in vivo changes in regional glucose uptake (GU) in the brains 
of C57BL/6J mice exposed to a single dose of METH (10 mg/kg). Our analysis focused on 
regions receiving relevant dopaminergic input typically affected by METH, such as the prefrontal 
cortex (PFC), the striatum and the hippocampus. Interestingly, the dose of METH used led to 
motor activation, but did not affect GU in any of the evaluated regions (manuscript under 
preparation). 
IGF and EGF receptors are known to phosphorylate a variety of intracellular effector 
proteins, such as Shc, which generates a recognition site for the SH2 domain of GRB2. GRB2 
is an adapter protein with 23 kDa where its SH3 domain mediates the basal state association 
with SOS, a 170 kDa guanylnucleotide exchange factor for the p21 GTP binding protein Ras. 
The IGF/EGF-mediated assembly of Shc-GRB2-SOS ternary complex is generally thought to be 
the major pathway leading to Ras activation. Recent studies have demonstrated that insulin 
treatment results in a feedback serine/threonine phosphorylation of SOS, which directly 
correlates with the dissociation of the GRB2-SOS complex. Furthermore, inhibition of this 
feedback phosphorylation of SOS preserves the interaction between GRB2 and SOS and 
prolongs the GTP-bound state of Ras. However, other studies provide evidence that alternative 
pathways to GRB2 may also contribute to SOS-mediated Ras activation (Okada and Pessin 
1996).   In our study, IGF-1 is strongly downregulated, and both gene levels of GRB2 and SOS-
1 are upregulated. However, the lack of differences in the gene expression of SHC or RASA1 
(Ras protein activator), do not allow to conclude that RAS could be activated with METH 
treatment. Moreover, the fact that a variety of cell processes occur through phosphorylation and 
other by posttranslational modifications make any conclusion based on mRNA levels somewhat 
fragile.   
 GRB10 (also known as insulin receptor-binding protein GRB-IB) encodes a growth 
factor receptor-binding protein that interacts with insulin and insulin-like growth-factor receptors. 
Overexpression of some isoforms of the encoded protein inhibits insulin/IGF-1 signaling and 
results in growth suppression. Post-translationally, RPS6Kα1 (Ribosomal Protein S6 Kinase, 
Polypeptide 1 alpha) also known as S6k, is involved in GRB10 phosphorylation that interacts 
with the cytoplasmic domain of the autophosphorylated insulin receptor which is then inhibited. 
In fact, both GRB10 and IRS-1 work by suppressing insulin or IGF-1 signaling upstream of 
phosphatidylinositol-3-OH kinase PI(3)K, blocking mTOR pathway (Liu, Gan et al. 2013).  
Our results showed that S6K (2.39), SOS-1 (6.02), GRB2 (2.83) and GRB10 (2.18) 
genes are both upregulated on METH-treated animals, which in combination with the IGF-1 (-
8.85) downregulation could mean that METH inhibits the insulin-signaling pathway. In line with 
this hypothesis, RT-PCR for IGF-1 and the respective IGF1 receptor gene expression was 
performed on striatal samples of METH and ALC/METH treated animals in order to better 
address it (see section 1.4). 
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3.1.4 Signaling players 
Among PI3K-AKT signaling pathway members, several regulators or intermediates of 
cellular signaling were found with altered gene expression after METH exposure. Most of them 
could be activated by different stimulus or sub-pathways, which rends the identification of a 
main target quite hard.  
RPS6ka1 is a protein encoded by RPS6Kα1 gene that showed an increased fold 
change (2.39) expression on METH-treated animals when compared to controls. RPS6ka 
belongs to a family that has been implicated as signaling intermediates in the cellular response 
to several growth factors, and due to its kinase catalytic domains it phosphorylates various 
substrates, including MAPK signaling pathway members (Moller, Xia et al. 1994). The activity of 
RPS6ka has been generally implicated in controlling cell growth and differentiation. Otherwise, 
some studies show that RPS6kA interacts with TSC2 (Tuberous Sclerosis 2), a protein encoded 
by TSC2 gene. TSC2 gene seems not to be altered 24h after the exposure to METH, although 
its partner TSC1 (also known as hamartin) does. TSC1 protein is known to interact with TSC2 
and the complex formed regulates and inhibits the growth factor-stimulated phosphorylation of 
RPS6Kβ1 (Ribosomal Protein S6 Kinase, Polypeptide 1 beta) and Eif4ebp1 by negatively 
regulating mTOR Complex 1 signaling (Dann, Selvaraj et al. 2007). Other roles have been 
identified for TSC1, namely the regulation of the vesicular transport and docking and the 
involvement on events of ischemia resistance on hippocampal neurons (Papadakis, Hadley et 
al. 2013). The effective role of TSC1 upregulation is unknown but it may work as a protective 
mechanism against an injury stimulus like METH. 
IRAK1 is a gene that encodes the interleukin-1 receptor-associated kinase 1, one of two 
putative serine/threonine kinases that become associated with the interleukin-1 receptor (IL1R) 
upon stimulation. This gene is partially responsible for IL-1-induced upregulation of the 
transcription factor NFκB. In fact, METH-induced IL-1 mRNA expression is not consensual 
(Goncalves, Martins et al. 2008) and although NFκB is upregulated in our study (2.20), this 
could not be sufficient to explain the increased expression of IRAK1 gene (2,23) observed after 
METH exposure. Importantly, nor toll-interleukin 1 receptor domain-containing adaptor protein 
(TIRAP), nor toll-like receptor (TLR4) mRNA levels assessed in this array are altered, difficulting 
the identification of upstream targets for METH action. Recently, new insights on IL-1-induced 
neuroinflammation of the BBB reveal that integrin β1 is the major adhesion receptor for 
endothelial cell attachment to extracellular matrix molecules. Moreover, it was found that 
integrin β1 critically regulates IL-1 β-induced ERK1/2 and NFκB activation, and that integrin 
activation occurred concomitantly with increased IRAK-1 activation (an hallmark of IL-1 
signalling) (Summers, Kangwantas et al. 2013). 
MTCP1 (mature T-cell proliferation 1) gene was identified by its involvement in some 
genetic translocations associated with mature T-cell proliferations, encoding for TCL1 protein, 
which may be involved in leukemogenesis. The prevailing view of the role of TCL1/MTCP1 
proteins in tumorigenesis is related to their involvement in the AKT signal transduction pathway. 
However, the mechanism by which TCL1 increases Akt activity is not completely known and 
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remains controversial. Other roles for TCL1 were investigated using animal models, and 
allowed to verify its role in T- and B-cell growth and survival, including resistance to receptor-
induced apoptosis (Despouy, Joiner et al. 2007). This process of cell death through apoptosis is 
known to occur concomitantly with G1 phase cell-cycle arrest, possibly explaining its 
involvement with CDKN1B (Le Toriellec, Despouy et al. 2008). The central role of PKC in T-cell 
physiology is supported by T-cell impairment in PKC-deficient mice associated with impaired 
activation of its downstream pathways, such as NF-B, ERK and AP-1 (Despouy, Joiner et al. 
2007). Nothing is reported about METH effects over MTCP1 expression and data provided by 
the present study do not allow to take any conclusion. 
Recent studies have revealed that cytoplasmic integrin-linked kinase (ILK) and its 
interactive proteins play important roles in several processes, including cell adhesion, cell shape 
change, migration, proliferation, survival, and differentiation (Wu and Dedhar 2001). ILK is 
directly bonded to the cytoplasmic domains of β1 integrin and connects integrins to the actin 
cytoskeleton by interacting directly with several proteins such as paxillin and parvin, thus, 
coordinating actin organization (Wu and Dedhar 2001; Rosano, Spinella et al. 2006). ILK 
overexpression and clustering results in the activation of a variety of intracellular signaling 
processes such as Akt phosphorilation and GSk3 inhibition, which lead to the activation of the 
transcription factor AP-1 resulting in the MMP-9 potentiation (Troussard, Costello et al. 2000; 
Wu and Dedhar 2001). In the present study, GSK3β mRNA levels were evaluated after METH 
exposure and no significant differences were observed when compared to control group (-1.24). 
In this context, some studies of METH exposure reveal that GSk3β inhibition leads to a gradual 
and sustained increase in TJs stability and attenuates BBB dysfunction in brain endothelial 
cells. In these particular studies, authors observed that GSk3β inhibition increases significantly 
the half-life of TJs, increasing consistently the amount of occludin and claudin-5 in cell 
membrane fractions (Rom, Fan et al. 2012; Ramirez, Fan et al. 2013). Moreover, it is well 
recognized that GSk3 activity is reduced by growth factors, enhancing β-catenin translocation 
into the nucleus (Holnthoner, Pillinger et al. 2002). 
Activation of AP-1 through the phosphorylation of GSk3β seems to be responsible for 
the ILK-induced expression of MMP-9. Moreover, results from endothelial cells showed that 
dephosphorylated GSk3β at specific residues suppressed MMP-9 protein, leading to the 
suppression of cell migration and invasion (Matsui, Assi et al. 2012). The evident upregulation 
of ILK on METH-treated mice (2.36) needs further study.  
Based on the information provided by this array and in combination with the IPA 
software, Network Analysis tool, an analysis of genes interaction was performed (Fig.2). This 
interactome construction was based in IGF1 and their respective connections, using mouse 
brain information. 
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Fig. 2 Interactome representation using IPA Software based on mouse brain information taking in account IGF1 
and their respective protein interactions. 
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3.2 Effects of ALC at gene expression of METH-treated animals 
 In order to address the protective role of ALC, an individual analysis of relevant gene 
expression was conducted. Based on the results obtained for METH exposures, a few 
candidates were selected and validated. 
 Due to the downregulation of mice IGF1 (-8.85) after METH exposure, we aimed to 
unveil the putative protective effect of ALC given before and after the drug insult.  Fig.3a shows 
that METH significantly decreases IGF1 levels (p<0.05). The pretreatment with ALC 200mg/kg, 
30 minutes before METH was able to counteract the decreased levels of mRNA (p<0.05, METH 
vs ALC/METH). However, no significant differences were observed when ALC is administered 
after METH. Moreover, ALC alone is not different from the saline control. Concerning IGF1R, 
there was also a significant downregulation 24h after METH exposure (p<0.01), which was 
prevented and reverted when ALC was administered (p<0.001, METH vs ALC/METH and 
p<0.001, METH vs. METH/ALC) (Fig.3b). 
 
 
Fig. 3 Representation of mRNA levels assessed through RT PCR for both IGF1 (a) and IGF1R (b). Data of n=3 were analyzed by CT 
method after normalization to housekeeping gene expression of GAPDH and GUSB. 
 
 
Regarding RhoGTPases, the literature has evidenced an effect of METH over RhoA 
and Rac1. In both the PCR array (Table 2) and the RT-PCR (Fig.4) we observed that METH is 
not able to alter significantly the levels of either RHOA or RAC1 mRNA levels. Therefore, the 
METH effect must occur at the level of protein activation rather than at gene expression level, 
since RhoGTPases are known to be activated posttranslationally. 
a b 
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Fig. 4 Representation of mRNA levels assessed through RT PCR for both RAC1 (a) and RHOA (b). Data of n=3 were analyzed by 
CT method after normalization to housekeeping gene expression of GAPDH and GUSB. 
 
 Although ILK was strongly upregulated in the PCR array, RT-PCR results do not allow 
to confirm this change (Fig.5a). However, based on evidence from the literature concerning 
METH effect on MMPs activity, we assessed MMP9 and MMP2 in the striatum of mice treated 
with METH and ALC. Our data showed that MMP2 mRNA levels were not altered after METH 
and/or ALC administration (Fig.5b). However, as expected, MMP9 mRNA levels were strongly 
increased in the mice brain after METH exposure (p<0.05). Moreover, we observed that ALC 
200mg/kg when given 30 minutes before METH was able to counteract this increase (p<0.01) 
which was not verified when METH is given after METH administration. Of note, ALC per se 
significantly increased MMP9 levels when compared to control (Fig.5c). The increased mRNA 
levels of gelatinases do not necessarily correlate with enzymatic activity augmentation, so 
further studies are needed to address this question. 
 
Fig. 5 Representation of mRNA levels assessed through RT PCR for both ILK (a), MMP2 (b) and MMP9 (c). Data of n=3 were 
analyzed by CT method after normalization to housekeeping gene expression of GAPDH and GUSB. 
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4. Conclusion 
Our study was focused on the PI3K-AKT signaling pathway since previous evidence 
strongly suggested the involvement of METH in cytoskeleton-mediated permeability. The 
present analysis allowed to verify that METH alters the expression of relevant proteins that 
could be involved in the signaling pathways that are triggered by METH exposure.  Our 
individual analysis of particular genes of interest contributed to point out which aspects of 
METH-triggered effects may be prevented by ALC administration. The present results pave the 
way to define which pathways are interesting enough to deserve further attention. We have 
identified 3 main targets that are now being addressed in our laboratory: ILK signaling that is 
addressed in the following chapters; IGF signaling that is being explored in the context of 
glucose uptake under METH exposure; and RhoGTPases signaling that is being explored for its 
role in synaptic and dendritic modulation in hippocampal neurons. The data obtained for IGF 
and for RhoA and Rac1 is out of the scope of the present dissertation and is therefore 
discussed elsewhere. 
Regarding the role of ILK pathway, we are particularly interested in exploring the 
modulation of MMPs, since there are several reports showing that METH exposure triggers 
MMP-2/9 release, which seems to play an important role in METH-induced disruption of the 
BBB function. Of note, nothing is known about METH effect in ILK expression. Based on the 
present data we reason that METH may increase the catalytic activity of MMPs (as has been 
described by other authors (Conant, Lonskaya et al. 2011; Martins, Baptista et al. 2011; Urrutia, 
Rubio-Araiz et al. 2013), and ALC may be effective in preventing these events. As ILK 
overexpression and clustering has been associated with an increased phenotype of 
invasiveness in some carcinomas (Wu and Dedhar 2001), whereas ILK silencing inhibits 
invasion (Troussard, Costello et al. 2000; Rosano, Spinella et al. 2006), we foresee that if ALC 
successfully prevents a METH-induced MMP activation, then it may also be of use in 
tumorogenic paradigms. This will be explored in Chapter 2. 
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CHAPTER II 
Acetyl-L-carnitine prevents methamphetamine-induced 
structural damage on endothelial cells via ILK related 
MMP-9 activity 
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“Life itself is your teacher, and you are in a state of constant learning.” 
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CHAPTER III 
Methamphetamine promotes α-tubulin deacetylation in 
endothelial cells:  the protective role of Acetyl-L-Carnitine  
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 “Learn from yesterday, live for today, hope for tomorrow.  
The important thing is to not stop questioning.”  
 
 Albert Einstein
 
  
  
  
  
93 
 
1. General discussion 
The interaction between the endothelium and the glial cells supporting neuronal function 
has gained increasing interest in the regulation of the BBB over the last few years. Impairment 
of BBB permeability has been strongly implicated in several pathologies such as stroke, trauma, 
multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy and brain tumors (Singh 
and Harris 2004; Abbott, Ronnback et al. 2006). Of particular interest is the similarity between 
BBB dysregulation caused by exposure to amphetamines and the neurophysiology and 
molecular pathology of some of the above mentioned neurological disorders (O'Shea, Urrutia et 
al. 2014). Psychostimulant drugs such as METH have been extensively studied in regard to 
their strong impact in the brain.  BBB is also recognized as a target for METH action, which 
adds to its neurotoxicity (Dietrich 2009; O'Shea, Urrutia et al. 2014). 
Due to the high prevalence of METH abuse throughout the world, it is important to 
unveil protection strategies to this neurotoxic compound. Among METH-induced neurotoxic 
effects, BBB dysfunction is a relevant one, since it can contribute to the development of other 
neurodegenerative pathologies and has been associated with other problems such as HIV-
related dementia (Mahajan, Aalinkeel et al. 2008; Reynolds, Mahajan et al. 2011). Data 
provided by recent investigation show that the prevention or reversion of BBB dysfunction could 
be a useful therapeutic strategy in conditions in which neuronal insult is secondary to BBB 
damage (Abbott, Ronnback et al. 2006; Dietrich 2009). 
The molecular mechanisms underlying METH effect on the BBB remain poorly 
explored. In this work, the in vivo screening of gene alteration after METH exposure was an 
important first step to better address METH action on signaling pathways regulating 
cytoskeleton and permeability events. These data provided preliminary clues on targets that 
could be involved in BBB dysfunction after METH exposure, allowing a more focused in vitro 
approach. This led us to explore the ILK pathway and its modulation of MMPs release on the 
cytoskeleton of the endothelial cells and how ALC could counteract the action of METH in this 
paradigm. Within the neurovascular unit, endothelial cells are the key players for the tightness 
of the barrier, and for that reason our experimental in vitro approaches were here carried out 
using an endothelial cell line that mimics part of the barrier properties. It is commonly accepted 
that MMP-induced leakiness at the BBB is a critical event for the development of several 
neurological diseases (Singh and Harris 2004). Adding to previous reports from other authors, 
we provided evidence that METH-induced MMP-9 activity is in fact regulated via ILK. 
Importantly, there is evidence that, at least in the case of METH, increased MMPs activity may 
be related to increased behavioral sensitization and reward (Mizoguchi, Yamada et al. 2004; 
Mizoguchi, Yamada et al. 2008; O'Shea, Urrutia et al. 2014), which are important factors for the 
addictive process. This effect may be related with the reshaping of the neuronal connectivity 
(particularly in the dopaminergic system), but may also be connected to changes at the BBB 
level (Mizoguchi, Yamada et al. 2008; O'Shea, Urrutia et al. 2014).  
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Here, as already mentioned, we show that MMP-9 activation occurs through ILK 
increased expression, along with structural changes in F-actin arrangement and claudin-5 
redistribution in the cell. We clarify that the METH-induced decreased TEER and increased 
permeability previously reported by other authors (Ramirez, Potula et al. 2009; Abdul Muneer, 
Alikunju et al. 2011) is associated with MMP-9-induced TJs disruption. These in vitro data is in 
accordance with the data obtained in our in vivo assays showing an up-regulation of ILK in the 
brain of METH-treated animals (Fernandes, Salta et al. 2014). 
Moreover, we have shown that METH also promotes deacetylation of α-tubulin, which is 
likely to impact the microtubule structure of the endothelial cytoskeleton and bound to further 
contribute to BBB dysfunction. Indeed, it was previously shown that microtubules deacetylation 
was associated with increased vascular permeability (Bogatcheva, Adyshev et al. 2007), while 
microtubule acetylation seems to be concomitant with the inhibition of barrier-disruptive 
pathways (Saito, Lasky et al. 2011; Gorshkov, Zemskova et al. 2012). Furthermore, we show 
that these events are associated with METH-regulation of HDACs. HDACs modulation by 
psychostimulants was previously reported and seems to be dependent on both the period and 
pattern of exposure (Omonijo, Wongprayoon et al. 2014). In particular, the effect of METH in 
microtubules acetylation at the cytoplasmatic level seems to be modulated by HDAC6 and 
eventually also by SIRT2, since it was recently confirmed that interfering with one of this 
deacetylases is sufficient to impair microtubule deacetylation (Yang, Laurent et al. 2013). In 
accordance we showed that METH promotes deacetylation of α-tubulin, which is likely to impact 
the structure of microtubules at the endothelial cytoskeleton and disturb the BBB function 
(Fernandes, Salta et al. 2014). 
It is possible that besides our findings concerning cytoskeleton remodeling, other 
parallel events may occur and contribute to the pathogenesis of METH-induced BBB. This is the 
case of previously reported oxidative stress and ROS, leading to leukocyte adhesion and 
vascular endothelial dysfunction (Dietrich 2009) and eNOS activation along with endocytosis 
across endothelial cells (Martins, Burgoyne et al. 2013; Park, Kim et al. 2013). Importantly, the 
role of microglia and astrocytes in this process is yet poorly explored, but likely to promote the 
release of extracellular factors capable to activating integrin receptors, triggering the cascade of 
events above described in endothelial cells.  
One important finding in this study is related with the mechanism of action of ALC in 
preventing BBB damage. ALC was previously shown to prevent the adverse effects of alcohol-
induced oxidative stress and METH-induced decreased glucose uptake (Rump, Abdul Muneer 
et al. 2010; Muneer, Alikunju et al. 2011; Muneer, Alikunju et al. 2011), but the molecular 
mechanisms involved were not addressed. Our work was the first to assess the mechanism of 
ALC as a neuroprotective agent over METH-induced impairment of BBB function. In this 
particular issue we conclude that a pretreatment with ALC prevented METH-induced ILK 
expression and clustering and the consequent activation of MMP-9, preserving claudin-5 
location and the arrangement of the actin cytoskeleton in an endothelial cell line. 
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Another important finding is the effect of ALC on acetylation processes, presumably 
mediated by HDAC6. In fact, more than 10 years ago, evidence already pointed toward an 
effect of ALC on post-translation processes, instead of an effect centered at the mitochondria. 
Pettegrew and collaborators compiled information showing that although carnitine plays a role in 
the β-oxidation of fatty acids, the acetyl moiety of ALC could be used to maintain acetyl-CoA 
levels and also to acetylate -NH2 and -OH functional groups in amino acids and possibly modify 
their structure, function, and turnover (for review Pettegrew, Levine et al. 2000). Based on this 
hypothesis, we investigated the ability of ALC to counteract the METH-induced decrease in 
acetylation levels on lysine residues of the α-tubulin cytoskeleton. We confirmed that ALC is 
capable of preventing the deacetylation of microtubules in endothelial cells exposed to METH. 
We hypothesize that this may also be related with the ALC effect on ILK modulation. ILK was 
shown to mediate MMP-9-release through regulation of GSK-3ß activity (for review see 
McDonald, Fielding et al. 2008), which in turn is known to interact and colocalize with HDAC6, 
enhancing its activity (Li, Shin et al. 2013). As there is evidence that ALC decreases GSK-3ß 
expression, it seems plausible that ALC mediation of HDAC6 activity may occur through GSK-
3ß inhibition. This is an interesting discussion point, because although ALC was recently 
proposed to be able to interact with HDACs directly by binding to zinc in their catalytic site 
(Huang, Liu et al. 2012), as described for TSA (Finnin, Donigian et al. 1999), in our work we 
could not observe a direct inhibitory effect of ALC over HDACs. Of note, the doses used by 
Huang and collaborators were much higher and led high levels of cell death which is not 
desirable in a protectant substance. 
With the present work we add important knowledge to the list of possible clinical 
applications for ALC. These features of ALC action are of further importance for future 
developments in the clinical management not only for drug abusers but also for patients 
suffering from other neurological disorders related with MMPs activation. Up on that, increased 
activity of MMPs is long known to be associated with tumor invasion and metastasis formation in 
several cancer types (Murphy, Ward et al. 1989; Johnsen, Lund et al. 1998); thus, we believe 
that ALC may become a useful target on development of selective inhibitors for MMPs, ILK and 
HDACs. Although further investigation is needed, our findings also show that ALC may be 
effective in reducing the activity of MMPs and HDACs without leading to severe co-effects, 
which rends it much less toxic than other treatments, such as TSA - a common inhibitor of 
HDACs that was associated with p21 increased expression leading to cell cycle arrest in both 
tumoral and normal cells (Westendorf, Zaidi et al. 2002). The hyperacetylation stage induced by 
compounds like TSA is still not well-characterized and is potentially harmful for the cell (Xu, 
Parmigiani et al. 2007). In that sense, the protection afforded through ALC may be more 
effective, leading to less severe side effects and be safely used for the purpose of HDACs 
inhibition.  
However, as mentioned above, further investigation is still needed before ALC can be 
safely used. Of particular relevance, is the study of the potential consequences of administrating 
ALC to healthy subjects, since in our lab we have seen that this may lead to altered cognitive 
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performance, which seems to be associated with increased synthesis of neurotransmitters as 
ALC is rapidly incorporated into glutamine, glutamate and GABA synthesis via the tricarboxylic 
acid (TCA) cycle (Scafidi, Fiskum et al. 2010). To the moment, clinical studies carried out were 
not conclusive and do not allow to assess the whole effect of this compound. Although ALC is 
being already prescribed and seems to have a promising therapeutic potential in several 
pathological conditions, more studies are still necessary to a better characterize its action. 
 
 
2. Global conclusion 
In summary, this dissertation shows that METH may affect the BBB function through 
regulation of ILK expression, which is associated with MMP-9 increased release and TJs 
dysfunction in endothelial cells. Furthermore, METH-exposure leads to HDACs activation and 
microtubule deacetylation, which also maybe a result of METH action at the ILK level. 
Importantly, we were able to show that ALC effectively prevents all these events contributing to 
maintain the cytoskeleton of the endothelial cells, which is essential for a proper barrier function. 
Despite the studies yet necessary before ALC can be used at the therapeutic level, these 
results provide valuable pre-clinical data with relevant translational perspectives. 
 
 
3. Future perspectives 
The obvious next step of this work is to obtain in vivo confirmation of the presented 
results. This can be achieved using a rat or mice model of exposure to METH and ALC, 
followed by evaluation of permeability parameters in brain regions of interest. Behavioral 
analysis can also be conducted to distinguish between the use of ALC and other pharmacologic 
approaches (such as the use of tubacin, a specific HDAC6 inhibitor).  
The role of GSK-3ß inhibition was not assessed in our endothelial model of exposure to 
METH. Overexpression of GSK3β in vitro, could reveal valuable insight into the mechanisms by 
which METH leads to of BBB dysfunction, since GSK3β inhibition was associated to a sustained 
increase in tightness of the barrier, with an increase of TJs on the membrane fraction (Ramirez, 
Fan et al. 2013). Understanding METH-modulation of this particular pathway, as well as the 
ability of ALC to counteract it will certainly allow a better comprehension of the events reported 
in the present work.  
Another issue that deserves further attention is the endothelial–astrocytic interaction (as 
well as the pericytes) in the modulation of BBB function under METH exposure. It is possible 
that damage to the endothelium and basal lamina may trigger the expression of signaling 
components that are important in barrier repair (Abbott, Ronnback et al. 2006). The cross talk 
between endothelial cell and microglia may also be of interest, since this may modulate MMPs 
release. Our preliminary data strongly suggest that microglia per se does not react to METH 
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stimulus while conditioned medium from astrocytes exposed to METH, modulates microglial 
reactivity to this drug. In fact, all components of the neurovascular unit will be necessary to fully 
explain METH-induced damage in the BBB level.  
Sophisticated methodologies were already designed to better mimic the functional 
properties of this very complex organ (Wilhelm, Fazakas et al. 2011; Naik and Cucullo 2012), 
but still need optimization to combine human brain-derived primary cultures for all cell types at 
the neurovascular unit, with a surrounding environment arranged in a 3D and dynamic 
apparatus. This model, along with sophisticated imaging tools will allow the assessment in real 
time to the function of this artificial BBB under METH-induced damage. 
Although a lot of challenges still persist, the molecular mechanisms unveiled in the 
present study will certainly help the design of therapies to protect the BBB function in the 
context of neurological injury. 
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Summary and conclusions  
Methamphetamine (METH) is a powerful psychostimulant drug used worldwide for its 
reinforcing properties. In addition to the classic long-lasting monoaminergic-disrupting effects 
extensively described in the literature, evidence strongly suggests the involvement of METH in 
cytoskeleton-mediated permeability. Indeed, METH has been consistently reported to increase 
blood-brain barrier (BBB) permeability, both in vivo and in vitro, leading to compromised 
function. As BBB dysfunction is a pathological feature of many neurological conditions, unveiling 
new protective agents in this field is of major relevance. Acetyl-L-carnitine (ALC) has been 
described to protect the BBB function in different paradigms, but the mechanisms underlying its 
action remain mostly unknown. 
Using an in vivo model of METH-treated mice, we focused on the phosphatidylinositol 3-
kinase/AKT signaling pathway to identify possible molecular targets in cytoskeleton-mediated 
permeability. We performed an array that allowed the identification of particular genes within 
this pathway that displayed altered striatal expression as a consequence of METH-exposure. 
These experiments allowed to verify that METH may alter the expression of relevant proteins 
that could be involved in the signaling pathways that are triggered by METH, paving the way to 
define which pathways deserved further attention in our study. ILK was one of those targets. 
Interestingly, nothing was known on how METH could affect ILK expression. We were 
particularly interested in exploring the modulation of matrix metalloproteinases (MMPs), since 
the involvement of the MMPs in the degradation of the neurovascular matrix components and 
tight junctions (TJs) is one of the most recent findings in METH-induced toxicity. Moreover, as 
there is evidence that psychostimulants drugs modulate the expression of histone deacetylases 
(HDACs) controlling post-translational changes in the cytoskeleton, and having in mind the 
impact of the tubulin cytoskeleton in critical cellular functions, we hypothesized that METH-
mediation of cytoplasmatic HDAC6 activity could affect tubulin acetylation and further contribute 
to BBB dysfunction. 
In order to assess the neuroprotective features of ALC in METH-induced damage, we 
used the immortalized bEnd.3 cell line. Cells were exposed to ranging concentrations of METH 
and the protective effect of ALC 1mM was assessed 24 hours after treatment. This dose of ALC 
was previously selected in our laboratory. F-actin rearrangement, TJs expression and 
distribution, and MMPs activity were evaluated. Integrin-linked kinase (ILK) knockdown cells 
were used to assess the role of ALC in ILK mediation of METH-triggered MMPs’ activity. 
Moreover, α-tubulin acetylation and the activity of HDACs were also assessed. 
Our in vitro results clearly show that METH led to disruption of the actin filaments 
concomitant with claudin-5 translocation to the cytoplasm. These events were mediated by 
MMP-9 activation in association with ILK overexpression. Pretreatment with ALC prevented 
METH-induced activation of MMP-9, preserving claudin-5 location and the structural 
arrangement of the actin filaments. Moreover, METH led to an extensive α-tubulin deacetylation 
mediated by HDACs activation, which was effectively prevented with a pretreatment with ALC. 
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Importantly, ILK was also shown to mediate MMP-9-release through regulation of glycogen 
synthase kinase (GSK)-3ß activity, which in turn seems to be necessary for HDAC6 activity, 
while ALC was reported to antagonize GSK-3ß, we hypothesize that ALC mediation of HDAC6 
activity may occur through GSK-3ß inhibition. 
Although further investigation is still needed, the present results support the potential of 
ALC in preserving BBB integrity, highlighting ILK and HDACs modulation as a new target for the 
ALC therapeutic use. 
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Resumo e conclusões  
A metanfetamina (MA) é uma droga de ação psicoestimulante do sistema nervoso, 
usada em todo o mundo pelas suas propriedades de ação ao nível do sistema de recompensa. 
Para além do seu efeito clássico na integridade do sistema dopaminérgico, várias evidências 
sugerem o envolvimento da MA na permeabilidade mediada por alterações do citoesqueleto. 
De facto, tem sido frequentemente descrita a capacidade da MA em aumentar a 
permeabilidade da Barreira Hematoencefálica (BHE), quer in vivo, quer in vitro, resultando num 
comprometimento da sua função. Tendo em conta que a disfunção da BHE é uma 
característica de várias condições de patologia neurológica, o estudo de agentes protetores 
nesta área reveste-se de extrema importância. A acetil-L-carnitina (ALC) tem sido descrita 
como agente protetor da BHE em diferentes contextos, apesar do seu mecanismo de ação ser, 
ainda, praticamente desconhecido. 
Através da utilização de um modelo in vivo de murganhos expostos a MA, este estudo 
focou-se na via de sinalização do fosfatidilinositol 3-cinase/AKT para identificar alvos 
moleculares reguladores da permeabilidade mediada por alterações do citoesqueleto. Para tal, 
procedeu-se à análise de um array que permitiu a identificação de genes pertencentes a esta 
via de sinalização que revelaram alterações de expressão ao nível do estriado, como 
consequência da exposição à MA. Estes ensaios permitiram verificar que a MA pode alterar a 
expressão de proteínas importantes da via sinalização sob a ação da droga, e desta forma foi 
possível definir quais as vias que requerem um estudo aprofundado. A cinase ligada à integrina 
(ILK) foi um dos alvos identificados. É importante salientar que até ao momento era 
completamente desconhecido o efeito da MA na expressão da ILK. Neste estudo, havia um 
interesse particular em explorar a modulação da atividade das metaloproteinases da matriz 
(MMPs), uma vez que o seu envolvimento na degradação dos componentes da matriz 
neurovascular e das junções de oclusão (JO) é um dos efeitos mais recentemente registados 
da toxicidade induzida pela MA. Para além disso, uma vez que há evidências de que as drogas 
de ação psicoestimulante modulam a expressão das histonas desacetilases (HDACs) que 
controlam alterações pós-tradução no citoesqueleto, e considerando que o citoesqueleto de 
tubulina desempenha funções críticas na célula, colocou-se a hipótese de que a atividade da 
HDAC6, citoplasmática, induzida pela MA, pudesse afetar a acetilação da tubulina e desta 
forma contribuir para a disfunção da BHE.       
Com vista ao estudo das características neuroprotetoras da ALC nas alterações 
induzidas pela MA, usou-se uma linha celular imortalizada - bEnd.3. As células foram tratadas 
com MA em diferentes concentrações e a ação protetora de 1mM de ALC foi analisada 24 
horas após o tratamento. A dose de ALC usada foi selecionada com base em estudos prévios 
no nosso laboratório. A organização do citoesqueleto de F-actina, a expressão e distribuição da 
localização das JO e a atividade das MMPs foram avaliadas. Foram igualmente usadas células 
onde foi induzido o silenciamento da expressão da ILK. Desta forma, foi possível estudar o 
papel da ALC na ILK enquanto mediadora da atividade das MMPs desencadeada pela MA. 
  
108  
 
Adicionalmente, procedeu-se à análise dos níveis de acetilação da α-tubulina, assim como da 
atividade das HDACs. 
Os resultados obtidos nos nossos ensaios in vitro mostram claramente que a MA 
provoca a desorganização dos filamentos de actina e a translocação da claudina-5 para o 
citoplasma. Verificou-se, ainda, que estes eventos são mediados pela atividade da MMP-9 em 
associação com a sobre-expressão da ILK. Um pré-tratamento das células endoteliais com 
ALC previne a ativação da MMP-9 induzida pela MA, preservando a localização membranar da 
claudina-5 e a organização estrutural dos filamentos de actina. Para além disso, verificou-se 
que o tratamento com MA resulta num extensa desacetilação da α-tubulin mediada pela 
ativação das HDACs, processo que é efetivamente prevenido pelo pré-tratamento das células 
endoteliais com ALC. 
É importante referir que a ILK já foi identificada como tendo um papel na ativação e 
libertação da MMP-9 através da regulação da atividade da glicogénio-sintase cinase 3ß (GSK-
3ß), a qual, por sua vez, parece ser necessária para a atividade da HDAC6. Uma vez que já foi 
descrito que a ALC antagoniza a GSK-3ß, supomos que a mediação das HDACs por parte da 
ALC deve ocorrer via inibição da GSK-3ß. 
Apesar de ser ainda necessária investigação adicional, os resultados apresentados 
nesta dissertação evidenciam claramente o potencial da ALC na preservação da integridade da 
BHE. Salienta-se a modulação da ILK e das HDACs como novos alvos para o uso da ALC a 
nível terapêutico. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
